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COLOCALIZATION OF NEURONAL CEROID LIPOFUSCINOSIS PROTEINS 




 The neuronal ceroid lipofuscinoses (NCLs) are a family of neurodegenerative dis-
eases predominantly affecting infants and children, which in some cases can present into 
adulthood. There are fourteen genes comprising the 13 known subtypes of NCLs (CLN1-
CLN8, CLN10-CLN14; CLN9 has been reclassified as CLN4). The NCL diseases share 
common molecular and clinical features, including cellular accumulation of autofluores-
cent storage material, characteristic histological findings (curvilinear inclusions, finger-
print profiles, and granular osmophilic deposits), markedly low brain weight, seizures, 
blindness, motor dysfunction and behavioral disabilities. Though the functions of the CLN 
proteins are not fully understood, they are mainly localized to the lysosomal compartment 
and autophagic pathway. Previous works have focused on understanding the individual 
functions of the CLN proteins. However, there is little research examining the interactions 
between CLN proteins and their involvement in neurogenesis. The CLN proteins also show 
involvement in various other signaling pathways, notably the mTOR and p53 pathways, 
and may therefore have implication as important signaling molecules during development 
and aging.  
In this thesis, I outline a variety of interactions between CLN proteins, as well as 
their role in lysosome formation and autophagy. I further examine the involvement of these 
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proteins in lysosomes of microglia, and potential functions of microglia during neurogen-
esis in childhood and adulthood. I hypothesize that the CLN proteins are likely involved in 
a common pathway which is highly regulated during neurogenesis through microglial re-
lease of pro-inflammatory molecules. Though these diseases are incurable, enzyme re-
placement shows promise as a treatment for NCL; cerliponase alpha (BioMarin Pharma-
ceuticals) is the first and only FDA-approved enzyme replacement treatment for CLN2 
disease. Future in-depth investigation of protein-protein interactions as well as their in-
volvement in signaling pathways during development is necessary in order to find a cure 
for these devastating diseases.  
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INTRODUCTION 
Neuronal ceroid lipofuscinoses (NCLs), generally known as Batten disease, are a 
family of inherited lysosomal storage disorders. Lysosomal storage disorders are diagnosed 
by an accumulation of autofluorescent storage material (ASM) in lysosomes, and in the 
case of the NCLs by their similar clinical presentations. Lipofuscin refers to a pigment 
typically found to accumulate in aging cells comprised of oxidized proteins and lipids, as 
well as carbohydrates and metals, while ceroid has been defined as a lipofuscin-like pig-
ment which was originally discovered in cirrhotic livers of rats72. While lipofusin accumu-
lation is a natural occurrence with aging, ceroid pigments typically accrue in response to 
cellular stress or other pathologies72. Both lipofuscin and ceroid pigments are considered 
components of the autofluorescent storage material seen in the NCL diseases. NCLs are 
most prevalent in children, occurring from as early as one year after birth, although there 
have been numerous cases of symptoms occurring later in life. Combined, this set of dis-
eases is the most common pediatric neurodegenerative disorder. Mutations in 13 different 
genes produce this class of diseases, which were classically characterized by age of onset, 
but classification now follows an axial nomenclature 
(https://www.ucl.ac.uk/ncl/newnomenclature.shtml). CLN1, CLN2, CLN5, CLN10, and 
CLN13 encode soluble lysosomal proteins. CLN3, CLN7, and CLN12 are transmembrane 
proteins; CLN6 and CLN8 are transmembrane proteins localized to the endoplasmic 
recticulum (ER). Lastly, CLN11 exists in the secretory pathway, while CLN4 and CLN11 
are found in the cytoplasmic domains45. CLN9 mutations have been reclassified as CLN4 
disease.  
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Currently, only five of the 14 NCL-causing proteins have known function. 
CLN1/palmitoyl protein thioesterase 1 (PPT1) is a palmitoylthioesterase which cleaves 
palmitate moieties from S-acetylated proteins. CLN2/tripeptidyl peptidase 1 (TPP1)  is a 
serine protease, CLN4/cysteine string protein alpha (CSP-α) is a heat shock protein 40 
(HSP-40) co-chaperone which functions in vesicle fusion and exocytosis, CLN10/cathep-
sin D (CTSD) and CLN13/cathepsin F (CTSF) are lysosomal proteases. They respectively 
cleave aspartyl and cysteine residues62. The remaining CLNs have undefined functions, 
although they are postulated to have roles in trafficking and fusion of vesicles, regulation 
of lysosomal pH, transport across the cell membrane, modulation of homeostasis and cell 
metabolism, as well as inflammation and tumorogenesis62. NCLs typically cause a variety 
of neurological and developmental issues, including visual impairment, intellectual disa-
bilities, seizures, and dementia. Their diagnosis is based on enzyme activity, blood analy-
sis, or skin biopsy for presence of storage bodies59. Currently, only one FDA approved 
treatment is available for CLN2 disease, the recombinant human TPP1 enzyme replace-
ment therapeutic Cerliponase alfa. The drug is delivered to the cerebrospinal fluid by in-
tracerebroventricular infusion every other week;  it enters target cells and is transported to 
the lysosome by the mannose-6-phosphate receptor. Once inside the lysosome Cerliponase 
alpha is cleaved to its activated form to replace non-functional TPP161. As for the remain-
ing NCL disease types, symptom management is the only option. There are currently a 
variety of preclinical and clinical studies which involve enzyme replacement, gene replace-
ment, immune modulation, and small molecule treatment for these diseases54.  
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Neuronal loss and microglial activation are characteristic of NCL diseases. In the 
developing brain, activated microglia are responsible for phagocytosing apoptotic cells, 
cytokine and growth factor release, and modifying neuronal organization33. Activation of 
microglia in the adult brain maintain these functions, and have been shown to mediate adult 
neurogenesis31. Microglia in their “resting state” do not appear to rest at all: these quiescent 
microglia are constantly surveying the brain environment33. Activated microglia release 
pro-inflammatory molecules in response to pathogens. During neurogenesis these mole-
cules are also released in varying amounts, though their functions in this process are not 
fully understood. Examination of microglial activation during neurogenesis may therefore 
prove valuable in understanding the neuronal loss seen in CLN diseases.  
Little is known about the molecular pathways the CLN proteins are involved in, 
however they show commonalities in regulation of apoptosis, cell survival, proliferation, 
differentiation, and inflammatory mediators, which may indicate a critical role of CLN 
proteins in these processes. In this paper I will present examples of cellular defects caused 
by CLN deficiencies, as well as evidence of multiple interactions among the CLN proteins, 
suggesting they operate together in a single pathway. Furthermore, I will explore the im-
plications of CLNs on neurogenesis and the roles of lysosomes in neurons and microglia, 
and how they may be responsible for shaping brain development from the embryonic into 
adult stages. Lastly, I will highlight the effect of inflammation on brain neurogenesis, and 
how CLN proteins may contribute to this process.  
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DISEASE PHENOTYPES AND PROGRESSION 
Clinical presentation of NCLs is classically characterized by age of onset. Over the 
past decade, new variants have been discovered that do not always fit the classical disease 
profile, which makes classifying mutations based on this categorization increasingly diffi-
cult. Nearly all of the NCLs present clinically with visual disturbances, seizures, and cog-
nitive decline. Brain pathology typically shows inclusions which have high affinity for os-
mium tetraoxide stain known as granular osmophilic deposits (GRODs), as well as ASM, 
but these are not limited to the brain. Skin biopsy and blood samples are typically used to 
diagnose NCLs, as these also contain storage bodies.   
Congenital neuronal ceroid lipofuscinosis (CNCL) or CTSD deficiency is the only 
known congenital form of NCL. Deficient neonates present with microcephaly, respiratory 
insufficiency and intractable seizures. Death follows within a few days of birth. Brain 
weight is markedly below normal, with atrophy of the cerebellum and loss of Purkinje 
cells, which are mostly responsible for GABAergic transmission of inhibitory impulses 
that regulate motor movement59, 11. Histological findings show characteristic accumulation 
of ASM and GRODs (Figure 1 A, D).  
Mutations in the CLN1 gene cause deficiency of the enzyme PPT1, leading to in-
fantile neuronal ceroid lipofuscinosis (INCL). Children become symptomatic between 10-
18 months old, presenting first with slowed development and motor impairment. Patients 
exhibit hypotonia and microcephaly, as well as progressive vision loss leading to blindness 
by approximately 2 years of age. Generalized seizures develop, and death occurs between 
ages 7 to 13. Infantile onset has also been observed in variants of CLN459.  
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Late infantile neuronal ceroid lipofuscinosis (LINCL) is caused by lack of TPP1 or 
TPP1 deficiency. Patients present first with seizures and impaired coordination near 3 years 
of age. Rapid vision loss, as well as motor and cognitive decline occur, reaching their peak 
by approximately 5 years of age. Cause of death in children with TPP1 deficiency is often 
infection due to hypothalamic disease that causes neutropic fever (fever without white 
blood cell reaction, which often leads to severe bacterial infection), as well as drug-resistant 
epilepsy. In CLN2 patients, brain weight is markedly low, with atypical physical charac-
teristics. There is widespread neuronal loss, and complete loss of cerebellar Purkinje cells. 
Staining of brain tissue shows PAS-positive granules, as well as evidence of apoptosis. 
CLN2, compared with the other NCLs, shows a strong presence of curvilinear inclusions 
(CRI) under electron microscope (EM) (Figure 1B). Rare mutations in CLN1, CLN5, 
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Figure 1. Inclusions seen under electron microscope common to NCL diseases. A., D. 
Granular osmophilic deposits (arrows; inclusions seen in A. lymphocyte, D. neuron). B. 
Curvilinear inclusions. C. Fingerprint profiles (enlarged in inset; inclusions seen in lyso-
some of lymphocyte). (Courtesy of Radke et al.43).  
Classical juvenile neuronal ceroid lipofuscinosis (JNCL) is characterized by CLN3-
deficiency or mutations that result in defective CLN3 protein. Symptoms begin around 4-
6 years after birth, with progressive vision loss occurring first. Cognitive decline and sei-
zures follow, as well as tremors, hallucinations and depression. Patients with CLN3 defi-
ciency often develop hypothalamic disease and experience periods of hypo and hyperther-
mia. In the later course of the disease, seizures become uncontrollable with little response 
to medication. Patients typically do not live past their mid-twenties, with few cases seen 
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into their forties. Patient brain weight at death is below average, and histological examina-
tion shows typical accumulation of auto fluorescent lipopigments. Autophagic vacuolar 
myopathy is also a common phenotype seen muscle tissue light microscopy (LM) (Figure 
2) and EM images of CLN3-deficient patients43, 66. In addition to this, there is significant 
loss of cortical neurons, as well as stellate and pyramidal cell loss. Apoptotic neurons are 
seen by EM, and some show fingerprint profiles (Figure 1C), a hallmark profile of many 
of the NCLs caused by lipopigment accumulation. While CLN3 is the most predominant 
gene contributing to JNCL cases, mutations of CLN1, CLN2, CLN8, CLN10 and CLN9 
that cause this similar age of onset are also seen. Phenotypes due to these mutations are 
variable, not always following the same progression as classical JNCL59. 
 
Figure 2. Autophagic vacuoles in muscle (arrows). (Adapted from Nishino71).  
Adult neuronal ceroid lipofuscinosis (ANCL) is caused typically by mutations in 
the CLN4 and CLN6 genes. Adult phenotypes have also been reported in CLN1, CLN10, 
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CLN5, CLN13 and CLN11. ANCL typically presents around 30 years of age, and shows 
autosomal dominant and recessive inheritance. Some mutations in CLN4 and CLN6 pro-
duce the recessive form (OMIM #204300), while other mutations of the CLN4 gene pro-
duce the dominant NCL type known as Parry disease (OMIM #162350). Patients typically 
experience epilepsy followed by dementia, behavioral abnormalities and impaired motor 
coordination. Atrophy of the cerebellum and cerebrum are evident, with variable loss of 
neurons and considerable Purkinje cell reduction59. 
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A CLN MOLECULAR PATHWAY? 
CLN PROTEIN DEFECTS 
CLN1/PPT1 
Identified in 199525, the CLN1 gene resides on chromosome 1p34.2 and codes for 
the enzyme palmitoyl-protein thioesterase 1 (PPT1). Mutations of this gene cause the dis-
ease known as infantile neuronal ceroid lipofuscinosis (INCL). This variant was originally 
thought to be among the Finnish population, but today there have been reported cases 
throughout Europe, the US, Canada, Turkey and India. The most common mutation is a 
nonsense R151X mutation, and a total of 69 mutations have been characterized that include 
various ages of onset.  
PPT1 removes cysteine-bound fatty acids, typically palmitate, from lipid modified 
proteins; notably, this is a reversible process with the forward reaction catalyzed by protein 
acyltransferases (PATs). PPT1 is found to localize specifically to lysosomes and late en-
dosomes, and is N-glycosylated at 3 positions. Mutations in these glycosylation sites can 
severely affect the enzymatic activity of PPT1 and its transport to lysosomes44. While all 3 
glycosylated forms are shown to be present in mouse fibroblasts, only 2 forms are seen in 
mouse neurons suggesting PPT1 has a specific function for neurons. When deglycosylated, 
Western blot analysis of the fibroblast PPT1 shows two bands of similar weight, while 
neuronal PPT1 exhibits a single band with molecular weight in the middle of the fibroblast 
bands. Lyly et al. have also studied the effects of two known ANCL and LINCL mutations 
on PPT1 activity and glycosylation, using the INCL form as a control due to its complete 
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inactivity. The ANCL mutation showed less than 5% residual activity but correct localiza-
tion, while the activity of the LINCL mutant was nearly that of the wild type enzyme. This 
mutation however showed reduced expression and restriction to the ER. In neurons, the 
ANCL and LINCL mutants were shown to have a higher degree of glycosylation than wild 
type (WT) PPT1, though this was not shown to cause defects in PPT1 complex formation44. 
This study did not find correlation between residual activity and age of onset, but did show 
that PPT1 may be involved in a yet unknown pathway for sorting proteins from the plasma 
membrane.  
Sapir et al. identified a number of interacting proteins with PPT1 and demonstrated 
PPT1s role in neuronal structure. 64 proteins were identified to interact with PPT1 in ex-
periments using mouse brain lysates from PPT1-/- and wild type mice, including 2 H+ vac-
uolar ATPases (v-ATPases). A statistically significant majority of these proteins are found 
to be palmitoylated, and computational predictions showed that some of the interactors are 
expected to be localized to the extracellular space as unbound or membrane bound proteins. 
Additionally, of the 64 proteins a significant portion were anticipated to be involved in 
cytoskeleton regulation as well as neuronal morphology5. 
By comparing dendritic trees of cultured mice hippocampal neurons, Sapir and 
coworkers discovered a significantly less complex dendritic tree than in wild type mice. 
This finding in conjunction with the functions of interactor proteins, prompted a search for 
changes in morphology in PPT1-/- dendrites. Dendrites are structures of neurons that re-
ceive and process signals from axons. Along the dendrite are processes called dendritic 
spines where excitatory signaling typically occurs60. Sapir et al. found that PPT1-/- mice 
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dendrites contained significantly less spines than WT mice, and a corresponding decrease 
in miniature excitatory postsynaptic currents (mEPSCs). Additionally, SYNCRIP, which 
binds specific mRNA, is suggested to modulate proteins involved in cytoskeletal and syn-
aptic structure. Sapir et al. showed a significant decrease in SYNCRIP localization within 
dendritic spines of PPT1 knockout (KO) mice5.  
Lange and coworkers further characterized the role of PPT1 in neurons through 
analysis of glial activation and astrocyte function. Under basal conditions, PPT1-/- astro-
cytes are shown to exhibit greater activation than their WT counterparts, as well as in-
creased soma size. Upon stimulation, these mutated astrocytes are activated further, shown 
through decreased soma size, in a similar manner as WT astrocytes. This is indicative of 
the maintained ability of PPT1-/- astrocytes to respond to stimulation. Astrocytes also ex-
hibit increased secretion of some soluble factors, corroborating evidence for increased ac-
tivation of PPT1-/- astrocytes. Furthermore, increased Ca2+ levels in the cytoplasm of these 
astrocytes suggests these cells are under oxidative stress56.  
PPT1-/- neurons, astrocytes and microglia exhibit changes in growth and survival 
compared with wild type cells. As was seen in PPT1-/- astrocytes, microglia show partial 
activation under both basal and stimulated conditions. When activated, microglia are 
known to produce inflammatory cytokines upon activation, including IL-1β. IL-1β is 
a pro-inflammatory cytokine, and increased IL-1β secretion is common pathology as-
sociated with NCL diseases. The researchers observed increased secretion of IL-1, in-
dicatice of oxidative stress in these cells. There also appears to be a significant decrease in 
cell number of cultured PPT1-/- primary neurons, as well as decreased number and length 
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of secondary and tertiary neurites. Together these indicate compromised neuronal mor-
phology and impaired survival. PPT1-/- astrocytes, cultured in the presence of either PPT1-
/- or wild type neurons showed decreased survival over WT astrocytes. Additionally WT 
neurons grown with PPT1-/- astrocytes exhibit decreased soma size and number of neurites, 
and over time begin to resemble PPT1-/- neurons. PPT1-/- astrocytes are thus implicated in 
changes to neural morphology. PPT1-/- microglia cultured with PPT1-/- neurons show sig-
nificantly greater neuronal cell death than either PPT1-/- neurons alone,  PPT1-/- microglia 
cultured with WT neurons, or WT microglia cultured with PPT1-/- neurons, therefore indi-
cating a possible role of PPT1 deficiency in neuron death. PPT1-/- neurons in the presence 
of PPT1-/- astrocytes and PPT1-/- microglia show the greatest level of cell death; in mouse 
models of CLN1 disease, early onset glia activation is shown to appear in the same regions 
of the brain exhibiting the greatest neuronal loss56.  
CLN2/TPP1 
The CLN2 gene was fully sequenced in 1998, and is located on chromosome 
11p15.4. Mutations of this gene code for the enzyme tripeptidyl peptidase 1 (TPP1), and 
cause late infantile neuronal ceroid lipofuscinosis (LINCL). There are known to be 129 
different mutations in this gene contributing to NCLs. TPP1 is an exopeptidase with limited 
endopeptidase activity, and is predominantly found in the lysosome and cleaves N-terminal 
tripeptides. It is synthesized as a proenzyme that is cleaved to its activated form under 
acidic conditions such as in the lysosome.  
Dictyostelium discoideum is an efficient amoeba model for a variety of human dis-
eases, including NCLs. D. discoideum (DD) contains orthologs for 11 of the 13 known 
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CLN genes. DD begins as a single celled ameboa, using bacteria as its main food source. 
Upon starvation, single-celled DD form aggregates, which continue to mature into what is 
known as a slug. Slugs can enter a migratory phase upon photostimulation, after which 
they may contract and grow upward to form the fruiting body as the final culmination phase 
of the DD lifecycle73. The greatest benefit of DD is its short lifecycle: maturation from the 
single cell phase to the fruiting body phase takes only 24 hours. Smith et al. used this model 
to uncover the effect of TPP1 loss on proliferation and growth throughout the amoeba 
lifecycle. DD mutants were generated via antisense inhibition to measure the effects of 
varying decreases in TPP1 mRNA. Accumulation of autofluorescent material was ob-
served in the mutant cells in a manner correlating with TPP1 mRNA expression. TPP1 
mutants were shown to develop more quickly into aggregates than WT controls. Addition-
ally, the number of total cells present during the slug phase of the life cycle were counted, 
revealing that TPP1 mutations cause a decrease in slug cell numbers which corresponds to 
mRNA level. Consequently, the fruiting bodies produced from the slugs also exhibit de-
creased size28.  
 TPP1 mRNA expression reaches its peak at approximately 16 hours, during the 
slug stage of development. Exposure to light or heat will induce the slug to enter the mi-
gratory stage. Upon exposure to light, mutants showed no impairment in initiation or di-
rection of migration, however the trails left behind by these slugs were markedly shorter 
than those of the WT. Smith and coworkers postulate this is due to the decreased size of 
the slugs leading to excessive loss of NH3; DD is known to migrate away from NH3, so 
more rapid depletion would likely result in earlier induction of the fruiting body stage. 
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TPP1 DD mutants additionally exhibited decreased growth, visible by reduced expansion 
on both bacterial lawns and in pure liquid medium. To explain whether decreased growth 
was caused by an impaired ability to digest nutrients, Smith and coworkers measured the 
rates of macropinocytosis and phagocytosis; TPP1 mutants exhibited significantly in-
creased rates of cytosis compared to WT DD. The researchers suggest this may be a com-
pensatory mechanism in response to starvation which is exacerbated by TPP1 deficiency28.  
 The target of rapamycin (TOR) pathway is an extensive signaling pathway respon-
sible for integrating signals that regulate cell proliferation, survival, growth and metabo-
lism. It is composed of 2 main complexes, mechanismic (formerly mammalian) target of 
rapamycin 1 (mTORC1) and mTORC2 (Figure 8); mTORC1 is critical in regulation of 
cell growth in response to cellular nutrition, and is important in inhibition of catabolic ac-
tivities such as autophagy; mTORC2 is found to be involved in growth and proliferation, 
survival, and cytoskeletal organization27. Considering the exopeptidase activity of TPP1, 
the researchers hypothesized TPP1 deficiency would result in decreased amino acid avail-
ability, thus inhibiting the TOR pathway. This was demonstrated through inhibition of 
mTOR by rapamycin treatment and antisense inhibition of Rheb, an upstream signal in the 
pathway. mTORC1 and mTORC2 are both sensitive to rapamycin, with effects seen in the 
mTORC2 pathway after sustained exposure. In WT DD exposed to rapamycin, slug cell 
numbers, fruiting body size, and growth rates were all decreased, while micropinocytosis 
and phagocytosis rates increased consistent with previous findings in TPP1 mutants. Sim-
ilar results were seen in the Rheb antisense inhibited DD. Rheb was also overexpressed in 
both WT and TPP1 mutant DD. Overexpression in the WT model increased growth while 
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decreasing rates of micropinocytosis and phagocytosis. Overexpression in mutants showed 
rescue of all mutant phenotypes, restoring them to near WT levels confirming the involve-
ment of TPP1 protein within this pathway28.  
 Mahmood et al. also observed TPP1 deficits in a zebrafish model of CLN2. 
Zebrafish have been used to study a wide range of diseases, and are useful considering their 
development can be easily observed. Zebrafish share TPP1 homology with humans, and 
mutants show similar phenotypes to CLN2 patients. Mahmood and coworkers engineered 
2 mutant genotypes, tpp1(sa0011+/-) and tpp1(hu3587+/-) which introduce premature stop 
codons in exons 3 and 11 respectively. Crossing parents of the same genotype result in 
tpp1(sa0011-/-) and tpp1(hu3587-/-) offspring. Interestingly, while all sa0011-/- offspring 
show mutant phenotypes, only 9.4% of hu3587-/- exhibit the mutant phenotype. It was con-
firmed this discrepancy was not due to death of hu3587-/- offspring, rather it is likely caused 
by mutation-dependent modifications of the disease course as is seen in humans. 48h post 
fertilization (PF), zebrafish-/- embryos appear to develop mutant phenotypes compared with 
WT fish. 72h PF, tpp1(sa0011-/-) develop a severely mutated phenotype, most notably de-
creased eye size and retinal area. Interestingly, tpp1(sa0011+/-) x tpp1(hu3587+/-) cross also 
produces offspring which develop a mutated phenotype. However, these offspring appear 
to have a protracted disease course as indicated by observation of mutant phenotype only 
after 72h PF, with development to the more severe phenotype after 120h PF69.  
 2 morpholino models, one resulting in irregular mRNA splicing and the other inhi-
bition of translation, showed similar phenotype to the tpp1(sa0011-/-) zebrafish 48h PF. 
TPP1 protein was absent in both the translation inhibited and sa0011-/- fish, while mature 
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TPP1 was seen 48h PF in WT fish by Western blotting. Splicing mutants showed additional 
transcripts not evident in WT. Mahmood and coworkers analyzed whole protein extract 
from -/- mutants, and discovered markedly reduced TPP1 activity, consistent with the ob-
served phenotype and Western blot results. Notably, TPP1 WT protein activity occurred in 
all layers of the retina, with the greatest accumulation in the outer nuclear and ganglionic 
layers which contain the cell bodies of rods/cones and ganglion cells respectively10. The 
activity in these layers is greatly reduced 48h PF69.  
 TPP1(sa0011-/-) mutants experience decreased survival rate similar to the human 
disease course. Mutants begin to die 4 days PF, with all offspring deceased at 7 days PF; 
all WT offspring were alive after 7 days. The mutants show increased accumulation of 
subunit c especially in the central nervous system (CNS) and muscle at 48 hours PF, as 
well as markedly enlarged lysosomes in the CNS. Mahmood and coworkers then examined 
a multitude of neuronal changes seen in these mutants. Anti-Hu C and anti-Hu D were used 
as indicators of neuronal differentiation by immunofluorescence. Splicing mutants and 
tpp1(sa0011-/-) zebrafish showed absence of both antibodies 48+ hours PF, with notable 
loss in the retina and cerebellum. Increased GFAP immunoreactivity was suggestive of 
astrocytosis. Analysis of apoptosis showed no change between WT and tpp1(sa0011-/-) 
mutants after 42 h, however apoptotic bodies were seen between 48 and 52 hours PF in 
CNS of mutants, which waned after 72 hours in neural tissue. Apoptosis in the CNS of 
mutant TPP1 fish corresponds to similar sites of cell death in CLN2 patient brains, par-
ticullarly in the retina, optic tectum and cerebellum. Phosphohistone H3, a marker of cell 
proliferation, showed a similar pattern of expression up to 48 hours PF in all genotypes, 
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with a noticeable decrease seen in the CNS from 48-72 hours PF in both splice and sa0011-
/- mutants. Disregulation of axonal tracts was evident 48 hours PF, resulting in loss of the 
optic nerve and trochlear nerve. Lastly, Mahmood et al. observed changed locomotion in 
mutant zebrafish consistent with seizure activity. Mutants exhibited frequent abnormal 
movement periods, larger swimming areas, and greater mean swim velocity at 48 hours 
PF; at 96 hours, fish show sustained muscle spasms and decreased movement compared to 
WT69.  
CLN3/Battenin 
 The human CLN3 gene was isolated in 1995, and is found to be conserved across 
many species. Human CLN3 is located on chromosome 16p12.1. Mutations of this gene 
cause the most predominant form of NCL, juvenile neuronal ceroid lipofuscinosis (JNCL). 
The most common mutation is an approximately 1 kB deletion. 
 Xiong and Kielian studied changes in microglia isolated from mice exhibiting the 
same 1 kB deletion as in the human CLN3 disease. IL-1β release from microglia is trig-
gered in a 2 step process: first transcription is activated to produce pro-IL-1β, after which 
the pro-peptide is cleaved in the cytoplasm to active IL-1β in the inflammasome complex. 
Induction of these steps in cultured microglia was triggered by a neuronal lysate and 
ceramide 6 (C6) respectively for this study32.  
 Inflammasome activation in response to neuronal lysate and C6 was markedly ele-
vated in CLN3 mutants, which led to increased IL-1β release from microglia of these mice; 
both of these events were necessary to elicit the response, as treatment with neuronal lysate 
or C6 was not sufficient for IL-1β release. Treatment of CLN3 deficient microglia with 
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lipopolysaccharide (LPS) and ATP was used as a positive control for initiation of the in-
flammatory response. LPS is typically used to invoke the innate immune responses leading 
to release of interleukins such as IL-1β. Surprisingly, this treatment elicited the opposite 
effect in these cells, causing reduction of IL-1β release. This was not further investigated 
as LPS would likely not be a significant factor in natural disease progression32. This would 
be an interesting response to explore as Ma et al. discovered LPS effects on 
CLN11/progranulin (PGRN) deficient mice as well13. Treatment with LPS may therefore 
be a useful way to understand inflammatory reactions in the NCLs.  
 In addition to IL-1β release, CLN3 mutant microglia were also shown to produce 
other cytokines and chemokines, namely the pro-inflammatory mediators TNF-α, FL-1α, 
IL-9, and IL-15; and anti-inflammatory mediator IL-10. CLN3 deficient and WT microglia 
exhibited no change in production of reactive oxygen species (ROS), and displayed com-
parable responses to oxidative stress which could not explain the pro-inflammatory pheno-
type.  
Specific inhibition of caspase-1 prevented IL-1β secretion suggesting that micro-
glial activation is caspase-dependent32. Furthermore, Xiong and Kielian observed a mas-
sive increase in glutamate release upon caspase-1 inhibition not seen in WT microglia 
treated the same way. This release occurred without any outside stimulation (including 
neuronal lysate or C6) and with no change in extracellular glutamate levels. Activation of 
hemichannels, which facilitate trafficking of small molecules through the plasma mem-
brane into or out of the cell, are likely involved in this phenotype as their activity was 
upregulated in CLN3 deficient cells. In media conditioned with activated CLN3 mutant 
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microglia, cell death was induced only in mutant primary cortical and cerebellar neurons, 
whereas WT neurons were resistant showing susceptibility of CLN3 mutant neurons to 
inflammatory stressors32.  
CLN4/DNAJC5/CSP-α 
 The CLN4B gene, most commonly referred to as DNAJC5, is localized to chromo-
some 20q13.33, and encodes cysteine-string protein alpha (CSP-α). Heterozygous muta-
tions in this gene are known to cause an autosomal dominant adult neuronal ceroid 
lipofuscinosis (ANCL), called Parry type NCL or autosomal dominant ANCL-4B.  
 Nieto-Gonzalez and coworkers explored the implications of CSP-α loss on neu-
ronal stem cell quiescence. CSP-α, part of the heat shock protein-40 family (HSP-40), has 
previously been shown as a requirement for maintaining SNAP25 stability at synaptic ter-
minals. In the hippocampus, CSP-α expression is prominent in radial glia-like (RGL) stem 
cells which are able to differentiate into astrocytes or neuronal precursors dependent on 
signaling processes. Nieto-Gonzalez and coworkers generated CSP-α KO mice, to further 
explore the effects in RGL stem cells. BrdU and Ki-67 are both markers of mitosis, and 
therefore are useful in examination of cell proliferation; brdU stains cells in S phase, while 
Ki-67 is able to stain cells in any phase. KO and WT mice were administered BrdU at 
postnatal day 10 (P10), and examined 5 days later. Hippocampi of CSP-α KO mice showed 
increased BrdU positive RGL stem cells compared to WT, indicating increased prolifera-
tion in these cells. At P30, many BrdU positive cells were also NeuN positive, indicating 
that proliferating cells showed differentiation into immature neurons. This was confirmed 
by increased Ki-67 expression indicating increased numbers of cells undergoing mitosis38.  
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 All RGL stem cells derived from mouse hippocampi were identified as nestin+ and 
sox+, while all dividing RGL stem cells were identified as nestin+, sox+ and MCM2+ 
(Figure 3). At P15, the number of total RGL stem cells in KO mice was comparable to 
WT mice, however mutants exhibit significantly higher numbers of dividing RGL stem 
cells. Moreover, the proportion of proliferating to total RGL cells was greatly increased in 
the KO mice. At P30, RGL stem cells pools were markedly reduced while the percentage 
of proliferating cells remained elevated. Together these results point to the necessity of 
CSP-α in preventing depletion of the RGL stem cell pool, and thus favors the quiescent 
state. Labeling of neural intermediate progenitor cells (nIPCs) by DCX showed an overall 
increased number of nIPCs in KO mice, and in the presence of MCM2 indicated an ele-
vated number of dividing nIPCs in the hippocampus. Nieto-Gonzalez and coworkers ob-
served greater distribution of MCM2+ cells throughout the granule cell layer (Figure 3). 
Measurement of miniature inhibitory postsynaptic currents (mIPSCs) indicated no notable 
changes in GABAergic signaling in cells taken from the dentate gyrus of KO mice between 
P10 and P1538. 
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Figure 3. Progression of neurogenesis with indicators for each cell stage. (Courtesy of 
Berg et al.78).  
Neurospheres are a useful method for examining nIPCs in vitro. The researchers 
grew murine CSP-α knockout neurospheres which appeared to develop normally aside 
from their larger size (Figure 4). The increased growth was likely due to increased mitosis, 
as there were a greater number of Ki-67+ cells in the KO cultures. Further investigation 
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revealed complete absence of SNAP-25, but no changes to other SNAP proteins. Of the 
pathways related to neural stem cell (NSC) proliferation, the researchers only observed 
changes to the PI3/Akt/mTOR pathway, shown through increased phosphorylation of the 
downstream target S638.  
 
Figure 4. Differences in neurosphere size in cultures of WT versus CSP-α KO mice NSCs. 
B. Neurospheres cultured from WT CSP-α mice in control (top left panel) and rapamycin 
treated culture (top right panel). Neurospheres from CSP-α KO mice in control (bottom 
left panel) and rapamycin treated culture (bottom right panel). C. Diameter comparison of 
cultured WT (top) and CSP-α KO (bottom) neurospheres. (Courtesy of Nieto-Gonzalez et 
al.38).  
Neurospheres were therefore incubated in the presence of rapamycin for 7 days to 
observe effects of mTOR inhibition. While S6 phosphorylation was inhibited in both WT 
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and KO neurospheres, the effects of inhibition were most evident in the KO. These neuro-
spheres were smaller than those not grown with rapamycin, showing mTORC1 hyperacti-
vation was likely the cause of overgrowth in knockouts. In vivo exploration of rapamycin 
inhibition support this theory. KO mice were injected with rapamycin from P10 to P30, 
after which the overall number of MCM2+ cells, including MCM2+ RGL stem cells, and 
the percentage of dividing RGL stem cells were greatly reduced and resembled WT num-
bers with no change in total RGL stem cell numbers. Remarkably, rapamycin injection of 
WT mice over the same period had no effect on any of the characteristics studied38.  
CLN5 
The CLN5 gene codes for CLN5 intracellular trafficking protein, and is located on 
chromosome 13q22.3. While the protein encoded by this gene is not fully characterized, it 
is known to be targeted to lysosomes where it functions as a soluble lysosomal protein. 
Mutations are responsible for the Finnish vLINCL, though mutations have now been de-
scribed across many diverse backgrounds.  
Savchenko and coworkers have been the first to describe the effects of CLN5 defi-
ciency on mouse neurogenesis. To study the in vivo effect of CLN5 deficiency, CLN5 
deficient brains from knockout mice were examined for changes in the number of immature 
neurons present compared to WT controls. Results indicated an increased number of NPCs 
and immature neurons at 5 and 7 months compared to WT, while these changes were not 
observed at 3 months of age. In vivo study of cells in the subventricular zones of mice at 7 
months indicated increased cell proliferation markers. This finding was corroborated by 
study of CLN5-/- hippocampal NPCs grown in culture. Compared with control, cultures 
   
 24
showed increased labeling by BrdU, an indicator of cell proliferation. These changes were 
not attributed to an increase in apoptosis, as there appeared to be no change from WT in 
mRNA levels of caspase-3 nor cleaved caspase-3, a known mediator of apoptosis40.  
Previous works have shown CLN5 mRNA is expressed in significantly higher con-
centrations in microglia than in neurons. Interestingly, Savchenko and coworkers found 
comparable levels of CLN5 in NPCs and microglia, highlighting the potentially important 
role of CLN5 in NPCs. Moreover, they found CLN5-/- NPCs show decreased ability to 
migrate, but increased differentiation. NPCs exhibit a phenotypic change, displaying an 
increase in number of neurites compared to WT NPCs; neurites are observed to be signif-
icantly shorter than controls40. CLN5 deficient NPCs also show reduced response to 
GABA, which has been shown to have an excitatory effect on NPCs and developing neu-
rons and may act in a negative feedback loop to regulate cell proliferation46.  
Changes in IL-1β levels have been shown to associate with changes in neurogene-
sis, although the exact mechanisms by which these changes occur has yet to be fully un-
derstood. At 7 months old, levels of IL-1β in CLN5-/- mice hippocampi were significantly 
increased, as were IL-1β levels in cultured CLN5-/- NPCs. In addition, increased IL-1β in 
the NPCs was accompanied by an increase in differentiating cells40. Interestingly, previous 
research has shown IL-1β release from glia lacking PPT1 is also increased56, which may 
indicate a common function of CLN genes in neurogenesis.  
Singh et al. expanded on the role of CLN5 in neurogenesis, in adult as well as in 
embryonic neurons. CLN5-/- and WT mice brains were used starting at embryonic day 14.5 
(E14.5), representing widespread CLN5 expression and peak embryonic neurogenesis. 
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CLN5-/- embryos show differential brain phenotypes, and an increase in Pax6 and p-H3 
immunoreactivity indicating increased proliferation of NSCs (Figure 5). Tuj1, a marker of 
early neurons, was decreased at E14.5 indicative of a defect in NPC differentiation. Both 
markers were no longer observed at E17.5 in CLN5-/- brains, showing that CLN5 is signif-
icant even before birth for proper neural development. Previous studies have shown Pax6 
may be involved in induction of differentiation, where expression of Pax6 is inhibitory. 
Singh and coworkers hypothesize that in NPCs deficient of CLN5, Pax6 expression is al-
ways on, causing arrest of differentiation to the activated neural stem cell (aNSC) stage39.  
 
Figure 5. Progression of qNSCs to mature neurons. aRGL cells, referred to in this paper 
as qNSCs, become activated (aRGL or aNSC in this paper) and can further divide into IPC. 
These divide and differentiate further, eventually becoming mature neuronal cells in the 
granule layer of the dentate gyrus. (Courtesy of Ghosh79). 
In contrast with the level of apoptosis seen in cultured CLN5-/- neurons by 
Savchenko et al.40, Singh and coworkers found that apoptosis of NSCs is increased in the 
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embryonic CLN5-/- mouse model at E14.5. Changes in the interneurons of E14.5 brains 
were also observed using calbindin, a marker for early interneurons. Significantly de-
creased immunoreactivity to calbindin was observed in the median ganglionic eminence 
(MGE), but no change was seen in the lateral ganglionic eminence (LGE) or dorsal telen-
cephalon (DT). The subpallium, together with the pallium, form the cerebrum; the subpal-
lium contains the lateral and medial ganglionic eminences, as well as the preoptic area. 
These areas are the site of GABAergic neuron generation. From here, newly born neuronal 
precursors migrate outward through the striatum, to the cortex (Figure 6). Lack of cal-
bindin activity in the median eminence of CLN5 deficient mice may be an indicator of 
dysfunction in interneuron development specific to the MGE; in agreement with this, Singh 
et al. observed a decrease in cells undergoing mitosis in the ganglionic eminences, although 
calbindin outflow from these regions suggests normal migration of these cells is unaffected 
in CLN5-/- mice. Investigation of interneuron persistence into adulthood indicated no 
change in the number of cortical interneurons, but levels in the hippocampus were signifi-
cantly reduced. Singh and coworkers also confirmed that neurite length is shortened in 
CLN5-/-, however they observed comparable numbers of branch points across genotypes39.  
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Figure 6. Migration of inhibitory (left) and excitatory (right) neurons during brain devel-
opment. LGE, lateral ganglionic eminence; MGE, medial ganglionic eminence; POA, 
proptic area, LP, lateral pallium; St, striatum; H, hippocampus. (Adapted from a review by 
Reiner26).  
As demonstrated by Singh and coworkers, there is evidence for dysregulation of 
GABAergic development. This idea is furthered by quantified changes in the expression 
of REST or neuron-restrictive silencing factor. REST is a factor expressed predominantly 
in non-neuronal cells, however research has shown that REST is also responsible for si-
lencing neuron-specific genes in neuronal stem cells18. REST expression is upregulated in 
the hippocampus of CLN5-/- mice at 6 months. REST was also shown to be a silencer of 
Gad 1 and Ptf1a, genes known to be important in GABAergic interneuron development. 
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CLN5 deficient mice exhibitied increased binding of REST to the Gad 1 promoter region, 
as expected from the increased REST expression. Expression of dominant negative REST 
was able to cause Ptf1a expression, while Ptf1a expression in control cells is not detected39. 
CLN6 
 Located on chromosome 15q23, CLN6 codes for a transmembrane ER protein, lo-
calized to the luminal domain12. Homozygous or compound heterozygous mutations in this 
gene cause variant late infantile neuronal ceroid lipofuscinosis (vLINCL) presenting with 
ocular involvement, or autosomal recessive adult neuronal ceroid lipofuscinosis 4A 
(ANCL-4A) also known as Adult Kufs Disease type A, presenting without retinal involve-
ment. 
 Benedict et al. discovered a novel interaction of CLN6 protein with CRMP-2, an 
important protein in neurite growth cone development. CRMP-2 also has implications in 
mediating neuronal polarity via microtubule assembly, regulating cytoskeletal interactions 
in axon outgrowth, and may also have a role in neuroprotection at synapses. CLN6 disease 
occurs naturally in a mouse model, nclf, which mirrors the genetic and phenotypic changes 
found in the human disease. Benedict and coworkers first used a yeast 2-hybrid system of 
CLN6 against human fetal brain cDNA, and discovered significant interaction of the cyto-
solic terminal of CLN6 protein with CMRP-2. These two proteins show coimmunoprecip-
itation in nclf fibroblasts, as well as colocalization to the cell soma and “distal extremities 
of cellular processes,”12. In 90 day old nclf mice, decreases in total CRMP-2 and inactive 
phosphorylated CRMP-2 were observed in the thalamus, with no significant changes in 
either level in the cortex.  
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 CRMP-2 is involved in semaphorin 3A (Sema3A) signaling, the signaling pathway 
directing neurite outgrowth. To investigate whether CLN6 deficiency affects CRMP-2 in-
volvement in this pathway, nclf neurons of the dorsal root ganglion (DRG) were co-cul-
tured with either Sema3A or Sem3F. Sema3A binding to its receptor causes phosphoryla-
tion and subsequent inactivation of CRMP-2, leading to inhibition of neurite outgrowth in 
a CRMP-2 dependent manner. Sem3F on the other hand also inhibits outgrowth in neurons, 
however this process does not involve CRMP-2. Interestingly, DRG neurons show no 
change in outgrowth in either medium, indicating proper function of the Sema3A CRMP-
2 dependent pathway. This further shows that CRMP-2 may have overlapping function in 
another pathway that contributes to the pathology of CLN6 disease12. 
 As CRMP-2 has function in neurite outgrowth, the researchers predicted that loss 
of the CLN6-CRMP-2 interaction may induce phenotypic changes in hippocampal neurons 
that contribute to disease pathology. Hippocampal neurons were isolated from nclf mice at 
E16.5, and cultured. There were no observations of altered morphology in these neurons 
up to day 4 in vitro, however at day 4 neuronal processes appeared underdeveloped and 
were not able to invoke many early synaptic connections as was seen in WT cultures. Fur-
thermore, this phenotype progressed by day 8 with processes appearing thinner and less 
complex. At the same time, the number of cells in culture was decreased by nearly half 
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CLN7/MFSD8 
 CLN7 or major facilitator superfamily domain-containing protein 8 (MFSD8) was 
discovered in 2007, and resides on chromosome 4q28.2. Mutations in this gene are known 
to contribute to variant late infantile neuronal ceroid lipofuscinosis (vLINCL). 
 The major facilitator superfamily (MFS) proteins are a group of transport proteins 
with substrates that include sugar, amino acids, and ions. MFSD8 has previously been re-
ported to localize to the lysosome, though like many of the NCL proteins, its function is 
not fully understood. Von Kleist et al. examined CLN7 deficiency in an immortalized cell 
line (Cb) from mouse granule progenitor cells of the cerebellum. Compared with WT cells, 
the CLN7 deficient line showed no change in morphology of any organelles. Induced dif-
ferentiation of CLN7-/- cells was unchanged as well, confirmed through visible expression 
of Map1b and Neun, two markers of differentiation70.  
 As NCLs primarily affect the lysosomal compartment, the researchers assessed Cb 
lysosomes further. Lysosomal associated membrane protein 1 (LAMP1) positive lyso-
somes were shown to be enlarged by nearly 30% compared to WT Cb cells, although there 
appeared to be no significant difference in the number of lysosomes present. Furthermore, 
CLN5 and CTSD levels are greatly reduced as confirmed by concentrations in total protein 
(60% and 50% decreases respectively) and lysosomal extracts, while CTSB, CTSL and 
LAMP2 levels were near normal. To understand the basis of these discrepancies, au-
tophagic flux was measured which showed no change from control in both nutrient-rich 
and nutrient-depleted environments with or without bafilomycin, an inhibitor of lysosome 
acidification. While CLN7-/- cells also show unaltered acidification of lysosomes, these 
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lysosomes were concentrated mostly to the perinuclear region of these cells, unlike in WT 
cells which exhibit lysosomes spread throughout the cytoplasm70.  
 To determine if CLN7-/- cells experience impaired motility, von Kleist and cowork-
ers looked at lysosomal distribution in the cytoplasm upon decreased cytoplasmic pH. This 
has previously been shown to initiate lysosome movement to the cell periphery. Consistent 
with decreased mobility, low cytoplasmic pH induced a majority of lysosomes in WT Cb 
cells to migrate from the perinuclear space, while few lysosomes in CLN7-/- cells were able 
to do so. Interestingly, inhibition of mTORC1 was able to produce the mutant phenotype 
in WT cells while no additional effects occurred in CLN7-/- cells. No defects were observed 
in cytoskeletal organization nor intralysosomal Ca2+ levels of mutant cells which could 
explain this impaired movement70.  
 Further investigation of mTORC1 activity during the starved state revealed that 
after 1 hour, mTORC1 activity was completely blocked in both WT and CLN7-/- Cb cells. 
This was measured through lack of phosphorylation of mTORC1 substrates, which was not 
restored after 24 hours of starvation in either genotype indicating that mTORC1 is not re-
activated after starvation despite normal autophagy. mTORC2 activity was also examined 
for similar defects. Phosphorylation of PKB/Akt kinase, a substrate of mTORC2, was de-
creased in both genotypes after 1 hour of starvation; after 8 hours of starvation, WT and 
CLN7-/- cells showed partial recovery of mTORC2 activity as measured by increased sub-
strate phosphorylation, however this was more pronounced in WT cells. Additional mTOR 
inhibition by torin 1 in nutrient-deficient conditions completely prevented Akt phosphory-
lation in both CLN7-/- and WT Cb cells, confirming the observed recovery was due to 
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mTORC2. The researchers also uncovered decreased cell survival in CLN7-/- Cb cells, in 
line with prior knowledge that Akt signaling is critical for delivering pro-survival signals 
to starved cells70.  
 Connolly et al. expanded on this work in a Drosophila model of CLN7 disease. 
Drosophila is known to have one orthologue of CLN7, which localizes predominantly to 
the optic system during early development, glia, and post-synaptic neuromuscular junction 
(NMJ) into adulthood. Furthermore it was found that CLN7 is present in the glia surround-
ing motor neurons as well as the body wall muscles forming the post-synaptic NMJ. Con-
nolly and coworkers sought to further examine the localization of CLN7 to the sub-synaptic 
reticulum (SSR) which homes the post-synaptic glutamate receptors. They discovered 
CLN7 is indeed localized to vesicles at this location, but these were not believed to be 
lysosomal structures4.  
 Simple innervation at the NMJ in Drosophila makes this a highly effective model 
for studying synapses. It was found that in CLN7 deficiency, the NMJ is much smaller, 
and the muscles exhibit decreased innervation by type 1b motor neurons. This subtype of 
motor neurons is responsible for tonic stimulation, and the decrease is likely caused by 
decreased synapse growth. Interestingly, no change was seen in the type 1s motor neurons 
responsible for phasic stimulation. Furthermore, type 1b contained fewer active neurotrans-
mitter release sites, while this phenotype was not observed in type 1s. CLN7 heterozygotes 
observed the same phenotype in the NMJ as homozygotes, indicating a critical role of 
CLN7 in synapse development4. 
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 Using RNA interference (RNAi), CLN7 expression was selectively inhibited at the 
muscular pre-synapse, muscular post-synapse, all glia, and glia specific to the Drosophila 
blood brain barrier (BBB). Connelly et al. revealed that changes only in the muscular ex-
pression of CLN7 are sufficient to cause the NMJ defects explained previously. RNAi in-
duced selective re-expression of CLN7 in the same locations was not sufficient to alleviate 
the phenotypes observed; only ubiquitous expression of CLN7 was able to completely res-
cue these defects4.  
 Connelly and coworkers next evaluated the effect of CLN7 deficiency on transmis-
sion of action potentials in the NMJ. Miniature excitatory junction potentials (MEJP) quan-
tified under varying extracellular Ca2+ concentrations were no different from those of WT. 
Under constant 5 Hz stimulation and 1 mM extracellular Ca2+, CLN7-/- deficiency signifi-
cantly impaired ability to recruit vesicles from the reserve pool for NT release, which was 
only mildly decreased in WT flies. Furthermore, NMJ defects appeared to promote muscle 
contraction defects in CLN7-/- larvae, which exhibit markedly decreased movement com-
pared with controls4.  
 In agreement with Kleist et al.70, Connelly and coworkers did not observe any in-
crease in autophagic flux in either the starved or fed states, suggesting normal autophagy 
in CLN7 deficiency. Inhibition of mTORC1 and mTORC2 by rapamycin and torin 1 was 
able to increase autophagic flux and thus increase the size of the NMJ in CLN7 deficient 
flies, further indication of operational autophagy. Examination of mTOR signaling in the 
post-synaptic compartment of muscle revealed reduced S6 phosphorylation (substrate of 
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mTOR1) in CLN7, while pre-synaptic staining of phos-S6 was comparable to WT signify-
ing dysregulation of this pathway only in the post-synapse. Rheb, an activator of mTORC1, 
was also colocalized and coimmunoprecipitated with CLN7, further evidence that CLN7 
is involved in post-synaptic mTORC1 signaling pathway4.  
CLN8 
 Homozygous or compound heterozygous mutations in the CLN8 gene are the cause 
of late infantile neuronal ceroid lipofuscinosis (LINCL). CLN8 resides on chromosome 
8p23.3. This gene codes for the CLN8 transmembrane ER and ERGIC protein. Allelic var-
iations in this gene also cause Northern Epilepsy, a Finnish variant of LINCL that appears 
to have been caused by a founder effect. 
 Galizzi et al. used another naturally occurring mouse model, mnd, to examine the 
effect of CLN8 loss on cellular stress responses. GRP-78 a major ER protein which inter-
acts with misfolded proteins, as well as CHOP and caspase-12, proapoptotic proteins acti-
vated in response to ER stress, were used as markers of ER stress in this study. In 1 month 
old mnd mice, levels of GRP-78 were shown to be elevated in all CNS structures, while 
CHOP levels were only elevated in the cerebellum, hippocampus, and retina. CHOP levels 
in the cortex and spinal cord were comparable to control mice. Activated caspase-12 also 
showed specificity to the retina. ATF6, an ER sensor protein responsible for expression of 
chaperone proteins including GRP-78 and CHOP, is able to migrate to the nucleus upon 
activation. Levels of active ATF6 were elevated in 1 month old mnd mice along with de-
creased expression of the inactive form further indicating potentially increased ER stress53.  
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 As is seen in the human CLN8 disease, mnd mice showed accumulation of auto-
fluorescent inclusions at 1 month of age. Purkinje cells showed the greatest levels of ASM, 
however these are also seen in the retinal, specifically in the outer nuclear, inner nuclear, 
and ganglion cell layers. Distribution of the storage material overlapped with increased 
CHOP and caspase-12 levels in these structures in mnd mice, whereas WT mice only 
showed weak caspase-12 activation in the inner nuclear and ganglion cell layers of the 
retina that were not statistically significant53.  
 To observe the downstream effects of caspase-12 activation, Galizzi and coworkers 
examined caspase-3 activation, which is cleaved from the inactive form by caspase-12. In 
1 month old nmd mice, capase-3 was found in the active form predominantly in the retina, 
cerebellum, and hippocampus, while no activation was observed in the cerebral cortex or 
spinal cord. At 4 months, mnd mice exhibited increased CHOP and activated caspase-3 
expression in the cortex and spinal cord, indicating a time dependent expression in these 
structures53.  
 Galizzi and coworkers also observed an upregulation of TRAF2 in mnd mice, 
which, when bound to IRE1-α, is known to induce protein kinases involved in inflamma-
tion, cell survival and apoptosis. Additionally, increased expression of TNF-α, TNFR1 and 
NF-kβ were observed in all CNS structures. Together these findings may uncover an in-
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CLN10/CTSD 
 The CLN10 or Cathepsin D (CTSD) gene discovered in 1982, is localized to chro-
mosome 11p15.5. This gene is ubiquitously expressed in humans, and mutations are clas-
sically known to cause congenital neuronal ceroid lipofuscinosis (CNCL). There are how-
ever 10 known mutations that cause disease phenotypes and age of onset consistent with 
CNCL, INCL, JNCL and LINCL.  
 Ketscher et.al. observed changes in mice with conditional knockout of CTSD by 
deletion of exon 2, causing premature stop codons that result in a non-functional protein. 
This mutation is specific to the neuroectoderm of developing mice (CTSD conditional 
knockout). Interestingly this deletion does not affect mRNA levels of CTSD, but protein 
expression was completely lost in KO mice. The researchers compared CTSD conditional 
KO mice to mice with a mutation resulting in ubiquitous loss of CTSD; both genotypes 
appeared healthy at birth, with normal development up to postnatal day 14 (P14). At P15, 
ubiquitous knockout mice showed decreased weight gain, while this was evident at P18 in 
conditional KO mice. At P17, ubiquitous KO mice begin to lose weight, and lose nearly 
half their bodyweight by P24. Conditional KO mice show intermediate weight loss during 
this period, with values between ubiquitous KO mice and WT. Ubiquitous mice typically 
died around P26, while conditional KO mice expire near P31, indicating that different de-
letions may contribute to protracted disease course24.  
 Expression of CTSD is predominant in neurons of WT mice between P14 and P31, 
and exhibit punctate expression indicative of their role in lysosomes. Conditional KO mice 
show expression of CTSD only in cells not derived from the neuroectoderm, and exhibit 
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upregulated CTSD expression beginning at P26 which is exacerbated by P31. Staining pat-
terns of CTSD in these mice are also vastly different from WT, and cells expressing CTSD 
appeared overloaded with this protein. Ubiquitous KO mice do not show expression of 
CTSD in any structures, however both these mice and conditional knockouts exhibit loss 
of neurons in the thalamus by P26. Interestingly, thalamic neurons develop normally until 
P14, showing comparable levels of NeuN positive cells across all genotypes24.  
 Investigation into the effects of CTSD loss on microglia activation by Ketscher and 
coworkers revealed differences between the 2 mutant genotypes. Markers of microglia and 
astrocyte activation, IBA-1 and GFAP respectively, were unchanged at P14 in any of the 
genotypes examined. At P26 however, both mutants exhibit extensive gliosis, increased 
microglia presence in the thalamus, and increased microglial activity, which was exacer-
bated by ubiquitous knockout of CTSD. Interestingly, no changes were observed in astro-
cytes at P26, while at P31 the conditional KO mice exhibit substantial increases in astrocyte 
presence. Furthermore, thymic and intestinal atrophy are seen in CTSD deficient mice, 
which followed the same progression as the other phenotypes, but is likely a secondary 
defect in CLN10 disease24. 
CLN11/PGRN 
Granulin (GRN), also known as progranulin (PGRN), is a 13 exon gene located on 
chromosome 17q21.31. GRN is inherited in an autosomal recessive manner, and homozy-
gous mutations in the gene cause adult-onset CLN11 disease (ANCL). Heterozygous mu-
tations in the GRN gene cause frontotemporal lobar dementia and primary progressive 
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aphasia. Processing of PGRN results in multiple granulins by alternative splicing. These 
granulins may be important factors in growth signaling.  
 Microglia are the main source of PGRN, and the protein is shown to localize to 
lysosomes. Götzl et al. explored the implications of PGRN knockout on lysosomes and in 
microglia. Through mRNA analysis on whole brain extract, they discovered PGRN-/- 
causes altered expression of various genes encoding lysosomal proteins. Among these are 
genes encoding Cd68, Cd63, and LAMP1, all of which showed increased expression. Hexb 
and CTSD, both lysosomal hydrolases, also showed an age-dependent increase in expres-
sion49.  
Götzl and coworkers further explored the increased expression of CTSD, the ca-
thepsin associated with CLN10 disease. In PGRN-/- mice, cleavage of CTSD into its light 
(1’) and heavy (2’) chain forms appears to be increased. In conjunction, proteolytic activity 
of CTSD also increases, however this increase deviates from wild-type mice only after 20 
months of age, before which levels are comparable in WT and PGRN-/-. This further indi-
cates the age-dependence of PGRN expression on CTSD. Two additional cathepsins, 
CTSB and CTSL, did not show any change in expression during youth but increasing age 
revealed changes similar to those seen in CTSD, together indicating a potential increase in 
lysosomal activity in PRGN-/- mice49.  
Mouse embryonic fibroblasts (MEF) from PGRN knock-out mice were analyzed to 
observe the effect of increased proteolytic activity and of maturation differences on protein 
turnover. Changes in cathepsins seen in vivo translated in vitro, with processing of CTSD 
to the 2’ chain form predominating over 1’ chain. Increased proteolytic activity of CTSD 
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and other cathepsins consequently lead to an increased rate of protein turnover and degra-
dation compared to PRGN overexpressed MEFs. This was exhibited by a decreased steady-
state level of degraded proteins that were not explained by changed mRNA expression of 
these proteins. Furthermore, there is also no indication that PGRN deficiency causes 
changes in autophagy that would account for increased protein turnover. Introduction of 
PGRN nor its processed granulins to PGRN-/- MEFs was also not sufficient to cause the 
observed changes in CTSD activity, indicating that under normal physiologic conditions, 
PGRN may not be directly involved in inhibition of cathepsin activity49.  
As earlier described PGRN is predominantly expressed in microglia, with 50-fold 
higher mRNA expression than in neurons. Interestingly, microglia derived from 3 month 
old PGRN-/- mice showed decreased CTSD processing to active forms, with no correspond-
ing change in enzyme activity; no change was seen in the other cathepsins tested. In 12 
month of PGRN-/- mice however, cortical fractions lacking microglia show increased 
CTSD levels and corresponding increased CTSD enzyme activity, whereas this was not 
observed in the same fractions from young mice. These changes may be explained by a 
compensation of lysosome processing by non-microglial cells49.  
 Ma et al. described a neuroprotective effect of PGRN. After traumatic brain injury 
(TBI), PGRN is shown to be critical for mediating the neuroinflammatory response by 
suppression of lysosome biogenesis. To further understand the role of progranulin in neu-
roinflammation, Ma and coworkers injected PGRN knockout mice with LPS, a toxin de-
rived from bacterial outer membranes that promotes neuroinflammation. Hippocampal 
PGRN mRNA levels were increased post-injection, and PGRN was colocalized with 
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CD68, an indicator of activated microglia. PGRN also mostly colocalized with LAMP1, 
confirming localization of PGRN in the lysosomes of hippocampal microglia. After LPS 
injection, both WT and PGRN KO mice showed elevated CD68 positive cells compared to 
control saline-injected mice. Despite the changes seen in both genotypes, PGRN knock-
outs showed the greatest increase in CD68 positive cells, an indicator that WT PGRN may 
suppress over activation of microglia and thus prevent excessive neuroinflammation in re-
sponse to stress13 (Figure 7).  
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Figure 7. Iba-1 and CD68 staining for microglia. Iba-1 is a general marker for microglia, 
and CD68 is a marker for activated microglia in WT and PGRN deficient mice. a c. Rep-
resentative staining and immunoreactive area for Iba-1 positive microglia.  b, d. Repre-
sentative staining and immunoreactive area for CD68 positive microglia in WT and 
PGRN deficient mice. (Adapted from Ma et al.13) 
 In WT and PGRN-/- cells 24 hours after LPS injection, concentration of brdU and 
Ki-67 positive cells significantly decreased, however distinction between the genotypes 
was not evident. 48 hours post injection, cell proliferation in WT mice appears to recover 
to near control levels, while PGRN-/- show sustained decreased proliferation suggesting 
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PGRN is important for protecting proliferating cells during neurogenesis. Furthermore, in-
creased mRNA expression of MPEG1 and Lyz2 (both markers of macrophages) in the 
hippocampus after LPS treatment was seen in both WT and PGRN deficient mice, with a 
more exacerbated expression in PGRN-/- animals indicating potential activation of micro-
glia localized to this area. CTSZ levels were also shown to increase in the PGRN-/- and WT 
mice after treatment, again intensified in the PGRN-/- mice which also may indicate in-
creased lysosome biogenesis in PGRN deficiency13.  
 Consistent with previous results shown by Ma and coworkers, mTOR mRNA levels 
in the hippocampus were increased in both WT and PGRN deficient mice, though levels 
were lower in PGRN-/-. This suggests that normal PGRN levels are important in modulating 
mTOR signaling and subsequently in decreasing lysosome biogenesis in response to stress. 
LPS treatment was also shown to increase levels of IL-1β and TNF-α, which were similar 
in WT and PGRN-/- treated animals. Significant increases in IL-6 and mPGES-1 expression 
were seen only in the PGRN-/- mice, and no changes in other inflammatory cytokines were 
seen between the two genotypes13.   
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COLOCALIZATIONS AND POTENTIAL INTERACTIONS BETWEEN THE 
CLN PROTEINS 
While there are evidently many areas of research that could improve the knowledge 
base of the NCLs, a functional understanding of the individual proteins and how they in-
teract is among the most important. Currently, there appears only to be a narrow spectrum 
of research involved in understanding the colocolizations and interactions, if any, of the 
CLN proteins with each other. As described in previous sections, mutations of the CLN 
genes cause similar phenotypes including histological findings, and compound heterozy-
gous mutations (where an individual may have two recessive mutations of the same gene, 
but these mutations are not the same) as well as mutations in more than one CLN gene have 
been shown to cause variability in age of disease onset and severity in NCL patients. Ad-
ditionally, CLN proteins have been shown to target to the same compartments, and expres-
sion is predominant in the CNS. All of these factors could indicate a possible connection 
between the CLN genes and proteins, leading to a potential metabolic pathway involving 
all of the known genes. Colocalization experiments using fluorescent microscopy are a 
useful way to determine whether proteins are localized to the same compartment, and may 
be a helpful starting point to infer potential protein-protein interactions. Colocalizations, 
also known as protein-protein proximity, which shows a high degree of overlap of fluores-
cent signals indicates that the proteins of interest are within close proximity74. Based on 
the similarities between the NCLs and the knowledge that these proteins have function 
specific to the lysosomal compartment, research has used colocalization experiments to 
   
 44
provide a better understanding of spacial overlap of the CLN proteins. Since protein-pro-
tein interactions depend highly on proximity between proteins, quantifying fluorescent 
overlap through future research may be able to show direct interactions between CLN pro-
teins. 
Zhong et al. attempted to prove this in 1999, through study of yeast Lac Z activa-
tion. CLN genes 1-3 were cloned and subsequently introduced into a yeast two-hybrid sys-
tem, creating 3 binding-domain (pB42AD/CLN1, 2, or 3) and 3 activating-domain con-
structs (pLexA/CLN1, 2, or 3). Yeast hybrids containing pLexA/CLN3 with 
pB42AD/CLN1, pLexA/CLN2 with pB42AD/CLN1, and pLexA/CLN3 with 
pB42AD/CLN2 were plated on media deficient of –Ura, -His, -Trp and –Leu, and rich in 
galactose, raffinose and X-gal. Growth of a positive control in the same media results in 
yeast colonies with a blue color, indicating activation of the LacZ gene and thus protein-
protein association of the two control constructs (pLaxA-53 with pB42AD-T). The tested 
hybrids all exhibited colony growth; however no color was observed leading to the conclu-
sion that these proteins do not interact in vivo. Interestingly, no hybrids were tested that 
involved pLexA/CLN1 with either CLN2 or CLN3 binding-domain constructs, nor 
pLexA/CLN2 with pB42AD/CLN3. The reasoning for this is unclear, and the 
pLexA/CLN1 construct is not mentioned again in the paper58.  
Based on these findings, Zhong et al. concluded that the CLN proteins do not inter-
act in yeast. It was suggested however, that since the yeast two-hybrid system requires that 
proteins be localized to the same cellular compartment, this model may not be most effec-
tive at studying interactions of these proteins. Additionally, the lack of available data for 
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other CLN variants at the time this study was conducted constrains these results58. Leung 
et al. confirmed these results in 2001 using a similar yeast model67.  
In 2002, Vesa and coworkers provided some of the first evidence of molecular in-
teraction of the CLN proteins. They transfected a COS-1 cell line with WT CLN5 protein, 
or one of the known CLN5 mutants: Finnish Major (FinM), European (EUR), or Swedish 
(SWE). They discovered native CLN5 is a 46.3 kDa protein with 4 possible methionine 
start sites at amino acids 1, 3, 50, and 62 producing four proteins with molecular weights 
of 46.3, 43.4, 41.5 and 40.3 kDa. Except for EUR, FinM and SWE were shown to produce 
truncated polypeptides. Previous studies have determined that CLN2 and CLN3 are a sol-
uble lysosomal enzyme and lysosomal membrane protein respectively. CLN5 was pre-
dicted to contain two hydrophobic regions contributing to possible transmembrane do-
mains, one of which was confirmed by Vesa et. al through membrane fractionation. Lyso-
somal associated membrane protein 1 (LAMP1) is a common marker used to determine 
whether CLN proteins are localized to the lysosome. Through antibody staining with CLN5 
and LAMP1 antibodies, it was shown that all four CLN5 proteins are co-localized with 
LAMP1 and are thus all targeted to the lysosomal compartment. FinM and EUR mutants 
also behaved in the same manner, while SWE was not tested23.  
Most interestingly it was found that CLN5 interacts with CLN3 and CLN2, and that 
mutated CLN5 prevents proper function of CLN2. Co-immunoprecipitation assays using 
antibodies specific to CLN2 or CLN3 proteins were shown in both cases to co-precipitate 
CLN5 protein, while CLN1 was not shown to associate with any of the other CLN proteins 
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tested, although supportive data are not published in this paper. Cells transfected with ei-
ther WT CLN5 or any of the three mutant CLN5 forms, and containing endogenously ex-
pressed CLN2 were immunoprecipitated with CLN2-specific antibody, then stained with 
CLN5-specific antibody. Only cells transfected with WT CLN5 showed bands indicating 
association with CLN2, while all mutants exhibited no bands by Western blotting. Cells 
transfected in the same manner but immunoprecipitated with CLN3-specific antibody and 
subsequently stained with CLN5-specific antibody all showed bands by Western blotting, 
indicating both WT and mutant CLN5 associates with CLN323.  
Persaud-Sawin et al. characterized the ability of non-corresponding CLNs to rescue 
each other in CLN1, CLN2, CLN3, CLN6 and mnd-/- mice, an animal model for CLN8. 
Human fibroblasts and lymphoblasts lacking CLN1, CLN2 and CLN6 exhibit decreased 
growth and increased apoptosis, as do CLN3-deficient cells (shown in previous studies). 
Mnd-/- mouse fibroblasts also show increased apoptosis, though interestingly their growth 
rate appeared accelerated in comparison with the other CLN deficient cells lines tested. 
Introduction of the corresponding CLN cDNA was found to significantly correct growth 
defects in all CLN types examined including mnd-/- fibroblasts transfected with human 
CLN8. In the presence of etoposide, a cancer chemotherapeutic known to induce apoptosis, 
these cells showed increased protection against etoposide-induced apoptosis, including 
mnd-/- genotypes which exhibited 80% protection from etoposide-induced apoptosis20.  
Examination of the effect of non-corresponding cDNA on the CLN deficient cell 
lines produced similar effects, though the interactions are shown to be specific. Cells with 
defects caused by deficiency in CLN1 and CLN2 were corrected with introduction of the 
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opposite cDNA construct, but show no change when transfected with any of the other CLN 
cDNAs. CLN3 defects were also partly corrected by CLN2, while CLN6 and CLN8 
cDNAs completely restored growth. Conversely, CLN6-deficient cells and mouse mnd-/- 
fibroblasts are restored to near normal by CLN2 and CLN3, as well as by reciprocal intro-
duction of each other’s cDNA. CLN1 cDNA showed no effect on any CLN deficient cells 
other than CLN2-/-. Increased protection from etoposide-induced apoptosis was shown in 
all of the above scenarios20.  
Persaud-Sawin and coworkers performed coimmunoprecipitation assays on cells 
with normal CLN proteins and showed co-precipitation of multiple CLN pairs. Reciprocal 
experiments show that CLN2 and CLN3 coimmunoprecipitate with each other, as does 
CLN2 with CLN6 and CLN8. CLN3, CLN6 and CLN8 also co-precipitate one another, 
suggesting a possible connection between all four proteins. Consistent with previous find-
ings, CLN1 only co-precipitates with CLN2. To corroborate this evidence, co-localization 
of the native proteins was also examined and results were consistent with the immunopre-
cipitation results. CLN2 is co-localized with CLN3 and Cathepsin D, whose deficiency 
causes the congenital form of neuronal ceroid lipofuscinosis, CLN10. CLN6 also showed 
co-localization with CLN2 and CLN3, and CLN8 co-localized with CLN6, CLN3 and 
CLN2. Co-localization of CLN1 with the other four proteins was not tested. Co-localiza-
tion of known mutants was also not tested20. 
Lyly and coworkers were able to confirm the interactions seen by Vesa et al. in-
volving CLN5, CLN2, and CLN323; in addition they discovered novel interactions of 
CLN5 with other CLN proteins. Previous studies have determined that CLN2/TPP1 is a 
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proenzyme, and is cleaved to its mature form in the lysosome63. It was shown in a GST-
CLN5 pulldown model that CLN5 predominantly interacts with the mature CLN2 protein 
versus the precursor. GST-CLN5 was able to also pulldown CLN1, CLN6 and CLN8 pro-
teins. Trafficking of CLN1, CLN3, CLN6 and CLN8 in CLN5 deficient mice fibroblasts 
appears to be the same as in those with WT CLN5. A trafficking-deficient CLN5 protein 
(CLN5-TD) which is synthetically retained in the ER was utilized to further understand the 
trafficking patterns of these CLN proteins. Lyly et al. discovered that in this system, CLN5-
TD caused CLN1 to be retained, without disrupting CLN2, CLN6 and CLN8 trafficking. 
CLN5 FinM is a naturally occurring mutant also restricted to the ER, and rescue of this 
mutation by overexpression of CLN1 causes proper trafficking of both proteins. Con-
versely, CLN1 mutants retained to the ER were not sufficient to cause retention of CLN5 
despite maintenance of the protein-protein interaction17.  
CLN3 is also shown to regulate CTSD levels, and solute conditions affect expres-
sion levels. Examination of osmolar effects caused by CLN proteins is important in under-
standing lysosome dysfunction, as maintenance of lumenal ion concentrations are neces-
sary (in addition to lumenal acidification) to proper lysosome function and membrane po-
tential76. Studying the effects of osmotic flux in CLN deficient kidney cells, the most prom-
inent site of osmolar changes, may help in understanding this aspect of NCL diseases. Cár-
cel-Trullols and coworkers examined the expression of CLN3 in baby hamster kidney 
(BHK) cells under hyperosmotic conditions. CLN3 expression under hyperosmotic condi-
tions is shown to increase in CLN3 overexpressed cells due to increased protein synthesis. 
Cells transfected with a CLN3 plasmid (C19) versus the empty vector (C2) both showed 
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increased lysosomal staining under hyperosmotic conditions, with C19 staining more 
prominent than C2. CLN3 and LAMP1 expression were clearly increased under these con-
ditions7. Levels of immature CTSD, the CNCL causing gene, do not change in response to 
significant increases in osmolarity, but expression of mature CTSD is found to be deter-
mined by CLN3 levels. C19 cells under isotonic conditions exhibited lower expression of 
CTSD than C2 cells, and hyperosmolarity caused a further decrease in CTSD expression 
for both cell types7.  
 Recently, Huber et al. used an amoeba model to understand the interactions and 
localization of MFSD8, the protein responsible for CLN7 disease. As previously described, 
the amoeba Dictyostelium exhibits a variety of CLN orthologs to humans, and is widely 
used to model CLN interactions. Huber and coworkers performed a BLAST sequencing 
analysis of human MFSD8 and discovered orthologs across many species. Yeasts and fungi 
were notably missing from this list, and may explain the lack of observed interactions of 
CLNs in the yeast two-hybrid model used by Leung and coworkers67. Another notable 
finding by Huber et al. shows that mutations of CLNs found in humans are also widely 
conserved across species34.  
 An ortholog of H+ vacuolar ATPase (v-ATPase) and p80, a protein known to be 
localized to late endosomes, were found to colocalize with MFSD8. These proteins how-
ever are not associated in immunoprecipitation assays, and thus show no direct interaction 
with MFSD8. GFP-pulldown of growth-phase versus starved cells was able to identify 
overlapping interactor proteins, many of which are involved in metabolism and biosynthe-
sis, and which show functional activity as activators and transporters in multiple cellular 
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compartments, including mitochondria. Among these interactors is an ortholog of 
CTSD/CLN10, which was detected by Western blotting. CTSD and other interactor pro-
teins also show overlap with CLN3 and CLN534. Limitations of GFP-pulldown are im-
portant to recognize, especially due to the fact that they can produce false positives through 
association with the GFP tag instead of the attached bait protein, so confirmation of these 
interactions is necessary. Table 1 provides a comprehensive list of the colocalizations ad-
dressed in this section.  
Table 1. Protein-Protein Proximity (Colocalization) of CLN Proteins.  
CLN Protein Colocalized CLN Proteins 
CLN1/PPT1 CLN2, CLN5 
CLN2/TPP1 CLN1, CLN3, CLN6, CLN8, CLN5 
CLN3 CLN2, CLN6, CLN8, CLN5, CTSD 
CLN5 CLN2, CLN3, CLN1, CLN6, CLN8 
CLN6 CLN2, CLN3, CLN8, CLN5 
CLN7/MFSD8 CTSD 
CLN8 CLN2. CLN3, CLN6, CLN5 
CLN10/CTSD CLN3, CLN7, PGRN 
CLN11/PGRN CTSD 
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LYSOSOMES AND MICROGLIA IN THE DEVELOPING BRAIN 
LYSOSOMES IN NEUROGENESIS 
Lysosomes are the site of intracellular digestion and recycling of materials. Lyso-
somal dysfunction is a hallmark of lysosomal storage diseases including NCLs, and in re-
cent years new information has prompted a reevaluation of the roles lysosomes play in 
cellular homeostasis and signaling. Lysosomal activation occurs when lysosomes fuse with 
autophagosomes, which induces acidification of the lysosomal lumen to allow for proteol-
ysis and degradation of the enclosed material. While lysosomes are found in nearly all cells 
throughout the body, they may play a specific role in neurons and the CNS. Lysosomes are 
found to be highly concentrated to cell bodies, and to a lesser extent dendrites, with the 
lowest concentration found in axons. This is not necessarily correlated with the rate of 
autophagy found in these areas, as the highest rate of autophagy is seen in axons. Autoph-
agosomes must fuse with lysosomes in order to degrade their materials, however it appears 
that in neurons autophagosomes instead mature into lysosomes as they are transported from 
the distal axon to the cell body19. These autophagosomes fuse with endosomes, which ac-
tivates retrograde transport to the cell body. During transport lysosomes become increas-
ingly acidic, and reach full degradative capability once they reach the cell body19. Interest-
ing, in all but CLN2 and CLN8 diseases, lysosomal acidification appears to be disrupted, 
although the molecular basis for this has not yet been completely identified. Functional v-
ATPase, a proton pump which is responsible for lysosome acidification, is necessary to 
maintain proper lysosome function as many lysosomal proteases are functional only at 
acidic pH. Interestingly, PPT1 deficiency has been identified to cause misrouting of a v-
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APTase subunit, which impacts lysosomal acidification77. Further study of CLN protein 
effects on lysosome acidification will help uncover the mechanism by which lysosome 
dysfunction occurs in these diseases.  
Lysosomes may be vital components for proliferation and differentiation of neural 
stem cells. Kobayashi et al. sought to understand the role of lysosomes in maintenance of 
quiescent neural stem cells (qNSCs). Neural stem cells are found in the subventricular zone 
and dentate gyrus of the temporal lobe/hippocampus, and proteolysis of embryonic stem 
cells mediated by the ubiquitin proteasome or lysosomal pathway prevents their differen-
tiation and is critical for maintaining a stem cell pool. Using similar reasoning, Kobayashi 
and coworkers discovered a greater increase in trypsin-like proteolysis in cultured mouse-
derived qNSCs compared with activated NSCs (aNSCs). Cathepsins A, B, F and LAMP1 
mRNA were shown to be increased in qNSCs compared to aNSCs; qNSCs show high ca-
thepsin activity as well as widely abundant transcription factor EB (TFEB), a master gene 
encoding many proteins involved in lysosome biogenesis. Additionally, there is indication 
that autophagy is increased in qNSCs48.  
 Inhibition of lysosomal degradation appears to be an important event in differenti-
ation of qNSCs. Based on the work by Kobayashi et al., lysosome accumulation indicated 
by high levels of cathepsins and LAMP1 is more evident in qNSCs than in aNSCs in 2 
week old mice neurons, shown both in vivo and in vitro. TFEB is inactivated by mTORC1, 
but in its active form is shown to be targeted to the nucleus. Activation of TFEB leading to 
subsequent increase in lysosome biogenesis appears to decrease proliferation of aNCS and 
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induces the quiescent state. To confirm this, TFEB-KO cells derived from mice were ana-
lyzed for lysosome abundance; this cell line exhibited decreased LysoTracker staining and 
decreased expression of lysosomal genes, indicating low abundance of lysosomes, while 
genes indicating activation of NSCs were upregulated. Together this indicates fewer lyso-
somes due to TFEB inactivation, and subsequent activation of NSCs, although this activa-
tion is not sufficient in causing further differentiation48.   
 Further evidence of lysosome involvement in neurogenesis is seen in work by Lee-
man et al., which focuses on their role in maintaining qNSCs in the aging brain. The re-
searchers examined differences in qNSCs and aNSCs from young and old mice. In general, 
qNSCs show increased expression of lysosome associated genes; TFEB motifs were in-
creased in these genes, and TFEB target genes showed increased expression in comparison 
to aNSCs. qNSCs were also observed to have greater staining for LAMP1, as well as 
greater number of and larger lysosomes. These lysosomes showed greater fusion with au-
tophagosomes to form autolysosomes, and while qNSCs contain many autolysosomes, 
their degradation abilities are altered from aNSCs. qNSCs show more protein aggregation 
in lysosomes than aNSCs, and inhibition of lysosomal acidity causes even greater protein 
aggregation and decreased growth factor response36.  
 Introduction of TFEB, the master lysosome regulator, was sufficient to decrease 
protein aggregation in qNSC, and allowed greater response to growth factors, indicating 
that lysosomal activation causes NSC activation. Interestingly, qNSCs show more age de-
pendent transcriptional changes than aNSCs, including changes in gene expression associ-
ated with lysosome function. Old qNSCs also show decreased lysosomal staining, and this 
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decrease was pronounced only in the qNSC population and not in aNSCs at any age. Re-
markably, qNSCs in aged mice reveal decreased autophagic flux, likely due to the decrease 
in lysosomes available for fusion with autophagosomes. Furthermore, the aged qNSCs 
show increased protein aggregation, which is diminished by lysosome activation. Together, 
these results indicate a major regulation of NSC activation dependent on lysosome activa-
tion36. Considering lysosomal dysfunction as well as neurodegeneration are predominant 
pathologies associated with NCL diseases, more in-depth study of how lysosomes affect 
neural stem cell population may shed light on how changes in neurogenesis contribute to 
the patterns of neurodegeneration seen in these diseases.  
MICROGLIA, THEIR ROLE IN APOPTOSIS, AND CONNECTIONS TO NCL 
Microglia are the resident macrophage of the brain, and unlike other macrophages 
derived from hematopoietic stem cells, microglia are derived early during development 
from yolk sac macrophages. Microglia are responsible for phagocytosis of cells generating 
pro-apoptotic signals as well as healthy, proliferating and mature neurons and neuronal 
precursors. In the postnatal brain they have also been shown to promote cell death for 
proper brain development. It is suggested that they have a role in regulating the NSC pool, 
in addition to regulating formation of astrocytes from RGL cells through phagocytosis of 
RGL radial cellular processes, and may therefore also have implications for inducing dif-
ferentiation of NPCs9. Furthermore, secretion of pro-inflammatory molecules from micro-
glia may be mediators of neurogenesis as well. Increased IL-1β levels have been identified 
in embryonic hippocampi, and are downregulated in the adult brain though still detectable. 
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IL-6 is also shown to promote NPC differentiation to gliogenesis, and overexpression re-
duces neurogenesis50.  
 Guadagno and coworkers investigated the role of IL-1β release on cell cycle arrest 
and apoptosis in NPCs of embryonic mice through activation of p53. The tumor suppressor 
gene, p53, is shown to have increased expression in NPCs during development and into 
adulthood. Lack of p53 increased proliferation and neurogenesis in NPCs, and reduced 
apoptotic cell death. NPCs cultured in the presence of activated microglia were much 
smaller and reduced in number compared to control cultures. Additionally, the number of 
actively dividing cells was markedly lower than control. By treating either microglia to 
prevent IL-1β release or NPCs to prevent IL-1β binding to its receptor, the researchers 
revealed an increase in proliferation and reduction of apoptosis in NPCs. They suggested 
that p53 is activated under inflammatory conditions produced by IL-1β, as evidenced by 
increased mRNA expression of p53 and its target genes (including p21, involved in cell 
cycle arrest, and PUMA and Noxa, both pro-apoptotic mediators) 30. Previous research has 
shown that longterm elevation of IL-1β causes decreased neurogenesis in the hippocampus 
of mice42. This may therefore be a useful mechanism to study the changes in apoptosis and 
neurogenesis seen in NCL patients.  
 Treatment with recombinant IL-1β (rIL-1β) caused activation of p53 and subse-
quently increased expression of p21 and PUMA. In the absence of p53, microglial activa-
tion is not sufficient to induce the changes seen in NPCs previously. p53-/- NPCs show 
reduced caspase-3 activation in the presence of activated microglia, as well as resistance 
to IL-1β induced apoptosis both of which were increased in p53+/+ NPCs. Downstream p53 
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target, PUMA, is known to be a mediator of mitochondrial outer membrane permeabiliza-
tion to induce apoptotic cascades. Interestingly, p53 deficient NPCs resisted outer mem-
brane permeabilization and thus apoptosis, further implicating inflammation in p53 medi-
ated apoptosis of NPCs30. 
 Sierra et al. describe the roles of microglia and apoptosis on neurogenesis in the 
adult brain. Apoptotic cells are shown to localize specifically to the subgranular zone 
(SGZ) of brain in young mice, and are removed by phagocytic microglia. Microglia pro-
cesses run throughout the SGZ, where they come in contact with nearly one-third of NPCs 
and neuroblasts. Under normal conditions, these microglia show no physiological changes 
from non-phagocytic microglia, indicating that activation is not necessary for phagocyto-
sis. Rather, microglial processes are able to change their shape in order to engulf apoptotic 
cells. Interestingly, microglia do not appear to phagocytose neuroblasts, nor immature neu-
rons marked as NeuN+, and no astrocytes were observed to affect apoptotic cells. The re-
searchers marked apoptotic cells to determine their stage of differentiation. Neuroblasts, 
immature and mature neurons were notably not identified, indicating that apoptosis occurs 
likely between the activated NPC and neuroblast stages31.  
 Examination by Sierra and coworkers of newborn neurons through BrdU labeling 
in 1 month old mice revealed peak expression of BrdU 2 days post BrdU injection, with 
exponential decline up to 15 days post injection. Apoptosis is evident 24 hours after injec-
tion, with the greatest percentage of apoptotic BrdU positive cells seen at 2 to 4 days post 
injection. Together these results indicated that a large portion of cells undergoing apoptosis 
are in fact newborn neurons. However, given that the proportion of apoptotic BrdU+ cells 
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to total BrdU+ cells was relatively small, it was hypothesized that the apoptotic cells are 
cleared rapidly by microglia in the SGZ. The greatest rate of apoptosis is seen 1 to 4 days 
after cell birth, during which activated NPCs appear to be the most common apoptotic cells. 
At 4 to 8 days, mostly differentiated neuroblasts are apoptotic, and rates of apoptosis de-
cline. In adults, the total numbers of neuroblasts and apoptotic cells are decreased, however 
no alterations are seen in phagocytic ability of microglia. Interestingly, microglia show 
increased activation with aging, accompanied by increased release of pro-inflammatory 
cytokines31.  
 To evaluate the effects of inflammation on microglia viability and efficiency, Sierra 
and coworkers induced the inflammatory response by administration of LPS. No differ-
ences were observed in NPC proliferation, however survival of mitotic cells was reduced 
compared to controls. This was largely due to a massive increase in apoptotic cells, which 
notably did not cause increased proliferation of microglia. Instead, microglia essentially 
increase their ability to phagocytose multiple cells at once, indicating that phagocytosis is 
not impaired by inflammation, rather it is increased31.  
 Most interestingly, a recent study has identified two populations of microglia in the 
brain. Burns et al. describe two subsets of microglia, those exhibiting autofluorescence and 
those without (AF+ and AF- respectively). AF+ and AF- microglia are found throughout the 
brain, with the greatest concentrations of AF+ microglia seen in the cerebellum, cortex, and 
hippocampus. The fluorescence is detected in a punctate manner throughout the cytoplasm 
of this microglial subset, and is shown to increase in an age-dependent manner. In mice at 
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3 months, AF+ microglia have shown “large storage bodies filled with osmophilic electron 
dense deposits52,” which have definitive curvilinear and fingerprint profiles.  
 AF+ microglia exhibit increased LAMP1 and CD68 positivity, indicating enlarge-
ment of the endolysosomal compartment, which, if disrupted causes greater accumulation 
of autofluorescence in this population. There are also significant differences seen between 
the AF- and AF+ subtypes, namely alterations in expression of specific proteins. Compared 
to AF- microglia, AF+ show general upregulation of proteins involved in the endolysosomal 
pathway (including LAMP1, CTSD, CTSF, PPT1, PSAP, and TPP1), trafficking proteins, 
endolysosomal fusion proteins (including PGRN), mTOR regulators, and those associated 
with neurons (including SNAP-25), oligodendrocytes, and astrocytes. Furthermore, path-
ways that appear to be enriched in AF+ microglia include autophagy, mitochondrial dys-
function, and mTOR deregulation. Lastly, upstream proteins involved in cell cycle regula-
tion, senescence, apoptosis, ER stress, autophagy, lysosome biogenesis and inflammatory 
responses are predicted to also contribute to the distinct phenotype seen in AF+ microglia. 
Together these indicate that AF+ microglia exhibit characteristics which are specific to this 
subtype52. Considering autofluorescence is a major indicator of NCL diseases, and that 
microglia are primed toward a pro-inflammatory phenotype in these diseases, this micro-
glial subset may indicate a specific role in NCL disease and should be further investigated. 
 Upon complete wipeout of all microglial populations, microglia are able to rapidly 
replenish themselves. AF- development occurs first, with AF+ microglia developing later 
and more slowly which suggest AF+ microglia develop directly from AF-. Intensity of au-
tofluorescence in the AF+ microglia also appears in a time dependent manner. Furthermore, 
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lysosomal dysfunction (as in CLN3 deficiency) causes an increase in autofluorescence and 
a change in the composition of autofluorescent material in the AF+ microglia specifically, 
with no changes seen in AF- microglia. Microglial death follows in an AF+-dose dependent 
manner. AF+ microglia can be further subdivided into AF(hi) and AF(dim) dependent on 
the intensity of autofluorescence. Aging is accompanied by progressive loss of AF(hi) mi-
croglia, corresponding with an overall decrease in microglia numbers. Apoptosis and cell 
death of both subsets increases with age, while AF- microglia exhibit 2x and 7x higher 
proliferation rates than AF(dim) and AF(hi) subsets respectively regardless of age. Finally, 
AF+ microglia also exhibit higher baseline levels of ROS, in addition to increased mito-
chondria levels. Interestingly, while ROS production increases with age, mitochondria con-
tent does not change52. Future research may benefit from further examination of this sub-
type of microglia, and their specific activity during embryonic and adult neurogenesis in 
patients with NCL disease.  
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LYSOSOME DYSFUNCTION AND ITS EFFECT ON MICROGLIA  
RESPONSE TO STIMULUS 
 Considering the importance of lysosomes in neural development, and their dysfunc-
tion associated with CLN proteins, investigation of microglial lysosomes may be helpful 
in understanding the relationship between microglia and neurons in CLN diseases. Dou et 
al. uncovered an ATP dependence on microglial migration in vitro, which had previously 
been discovered in astrocytes. Application of ATP and ATP gamma S (ATPγS, a less hy-
drolysable form of ATP) via pipette tip to microglial cultures shows migration of the cells 
toward the ATP source. Interestingly, hydrolysis of ATP resulted in no response of micro-
glia to ATPγS. Indeed, under normal conditions ATPγS application results in increased 
extracellular ATP, suggesting microglia release ATP in response to ATPγS. Furthermore, 
inhibition of ATP and ATPγS not only inhibits morphological changes and migration of 
microglia, but inhibits basal motility seen in this cell type29.  
 In microglia, ATP stores appeared to be more prominent in lysosomes than in mi-
tochondria. Interestingly, inhibition of oxidative phosphorylation induced ATP release 
from lysosomes. Under ATP stimulation, the lysosomal membrane fuses with the plasma 
membrane in a Ca2+ dependent manner, which is confirmed by an increased intracellular 
Ca2+ concentration. Creating an ATP gradient was able to induce elevated Ca2+ levels in 
surrounding microglia suggesting Ca2+ signaling in response to ATP is required for lyso-
some exocytosis. This is further evidenced by effects of lysosomal disruption on ATP re-
sponse. Microglia response to ATPγS is inhibited upon lysosome disruption. Moreover, 
disruption of lysosomal trafficking and exocytosis led to decreased migration of microglia 
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which were furthest from the ATPγS source, indicating microglia migrate in response to 
ATP release from lysosomes, and disrupting the lysosome prevents long-range signaling 
of microglia29. 
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DISCUSSION 
 The neuronal ceroid lipofusinoses are clearly detrimental diseases. They involve 
significant dysregulation of autophagy and neurogenesis, and are ultimately fatal. Most 
unfortunately, these diseases have no cure, and symptom management is the only option 
for improving quality of life for most subtypes. In this paper I have outlined evidence that 
loss of any one of the CLN proteins has severe implications for neuronal proliferation and 
differentiation, as well as apoptosis. These phenotypes are not confined to the neuronal 
population, as there are significant data showing microglial involvement.  
 Overall, I have presented evidence for interactions of 10 of the 13 CLN related 
proteins. These proteins may potentially be involved in a single pathway, which when dis-
rupted severely impairs neurogenesis and may be mediated by inflammation caused by 
microglial activation, a commonly observed pathology in NCL diseases. Colocalization 
experiements show promise for understanding potential binding interactions of CLN pro-
teins. CLN1 has been shown to colocalize with CLN220 and CLN517. CLN2 is able to in-
teract with CLN1, CLN3, CLN6, CLN820 in addition to CLN517, 23. CLN3 is shown to 
interact with CLN2, CLN6, CLN820, CLN517, 23, and CTSD7. CLN5 interacts with CLN2, 
CLN323, CLN1, CLN6 and CLN817. CLN6 interacts with CLN2, CLN3, CLN820 and 
CLN517. CLN7 associates with CTSD34, while CLN8 interacts with CLN2, CLN3, CLN620 
and CLN517. Lastly, CTSD has shown interactions with CLN37, CLN734, and PGRN (Götzl 
et al.), while PGRN shows extensive interaction with CTSD (Götzl et. al). These interac-
tions are summarized in Table 1.  
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In addition to these interactions, further studies have indicated time-dependent col-
ocalization of CLN2, CLN3 and CLN5 proteins during embryonic and postnatal neurogen-
esis22. Other studies have shown connections between PPT1 deficiency and CTSD, in 
which PPT1 deficiency causes overexpression of CTSD but leads to phenotypic effects 
similar to CTSD deficiency57. A similar type interaction has also been shown between 
CLN4/CSP-a and PPT1 where CLN4 deficiency results in altered PPT1 enzyme activity 
that contributes to CLN4 pathology21. Further studies examining the effects of CLN protein 
loss on expression of other CLN proteins should be done to understand whether these pro-
teins interact and affect a common pathway. 
 On their own, different CLN deficiencies have similar consequences, especially in 
the developing brain. Loss of CLN proteins have indeed caused altered morphology, se-
cretion, growth, proliferation, and apoptosis of neurons which may indicate a critical role 
in neuron development or neurogenesis. As CLN proteins are implicated in the autophagy 
pathway and mostly localize to lysosomes, I first examined differences in lysosome behav-
ior that are specific to neurons and found important roles of these structures in NSCs and 
NPCs. Interestingly, lysosomes are necessary for maintaining the quiescent state of NSCs, 
and lysosomal activation is the driving force for activation of NSCs48. Considering lyso-
some enlargement is seen in CLN269 and CLN770 deficiencies, enlarged lysosomes ob-
served in qNSCs may be regulated by CLN proteins. Evidence that lysosomes are involved 
in activation of NSCs in the aging brain36 further brings into question the role of lysosomes 
and CLNs in neurogenesis. Could loss of CLN proteins from the lysosomes of NSCs con-
tribute to age-related brain pathology? 
   
 64
To highlight another possible role of autophagy and the CLN proteins in neurogenesis, 
it is important to look at the changes in proliferation and differentiation seen throughout 
the CLN diseases examined here. Altered differentiation and proliferation are specific to 
the areas of the brain which house NPCs. While the CLN proteins have all shown function 
in the autophagy pathway, it is imperative to understand the role of this pathway in neuro-
genesis. Autophagy has been shown to regulate Notch signaling by degradation of the 
Notch receptor. Disruption of autophagy would therefore lead to altered Notch signaling65. 
Notch signaling between cells occurs when the Notch1 receptor on the receiving cell binds 
a surface-expressed ligand on the signal sending cell. Processed Notch is translocated to 
the nucleus where it interacts with CSL to regulate transcription of target genes to deter-
mine cell fate51. Constitutive activation of Notch has been shown to decrease proliferation 
and differentiation, and allows for self-renewal of progenitor cells55; alterations in autoph-
agy affecting receptor internalization and recycling may therefore contribute to the pheno-
types seen in CLN deficient models. There is evidence that CLN3 overexpression may 
produce a phenotype similar to Notch loss-of-function phenotype75. This may help explain 
the alterations in proliferation and differentiation seen in CLN3 disease, as well as other 
NCL diseases. 
Specific subsets of microglia are present in the brain whose physiology and presence 
vary with aging52. Most interestingly, these microglia show basal autofluorescence which 
increases with age. They contain enlarged lysosomes, and malfunction of the lysosomal 
compartment leads to greater accumulation of autofluorescent material. Considering the 
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lysosome pathology associated with CLN disease, the characteristic accumulation of auto-
fluorescent storage material, and the microglial involvement seen in multiple CLN sub-
types, these proteins may be important to this subset of microglia. This is corroborated by 
the increased expression of lysosomal proteins in the autofluorescent microglia, particu-
larly those proteins contributing to CLN disease including CTSD, CTSF, PPT1, and 
TPP152. Additionally, these microglia reside in the same areas of neuronal loss typically 
seen in CLNs and autofluorescent materials show similar ultrastructural features (curvilin-
ear and fingerprint profiles, and osmophilic deposits) seen in CLN pathology52, 59. The age 
related increases in autofluorescence, apoptosis, and proliferation of the different subsets 
of microglia 52 may be attributed to CLN proteins and requires further study to better un-
derstand their involvement.  
Activation of microglia and astrocytes is a common occurrence in CLN diseases, and 
CLN protein deficiencies have seen major implications in proper microglia function. Fur-
thermore, increased IL-1β release from microglia is seen in many of the NCL diseases, 
indicating inflammation as a possible key to understanding their progression. Increased 
baseline ROS production in the AF+ subset of microglia52, and increased ROS generation 
in some CLN diseases68 may be important signals both in neurogenesis and in disease pa-
thology. While apoptosis is a key event in neurogenesis and is mediated by non-activated 
microglia31, understanding the effects of inflammation on apoptosis may be useful in un-
derstanding associated pathologies. Activation of pro-inflammatory pathways has been 
shown to increase the number of NPCs which undergo apoptosis31. In CLN diseases, acti-
vated microglia release increasing amounts of pro-inflammatory mediators, namely IL-1β, 
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which may therefore contribute to the increased apoptosis seen in cells lacking these pro-
teins. Furthermore, as lysosomal dysfunction occurs, microglia may experience impaired 
migration29. This may result in increased accumulation of post-apoptotic cells and activated 
microglia to the SGZ, causing a feedback mechanism of microglia activation in response 
to dead cell aggregation. In turn, this may contribute to the neuronal loss seen in specific 
areas of the brain in CLN disease. Additionally, inflammation in the uterus has shown det-
rimental impact on fetal brain health, with significantly decreased neurogenesis seen at the 
post-natal stage41; anaylsis of maternal and uterine health may help in understanding the 
congenital form of CLN disease, and further examination of the inflammatory response 
and its effect on CLN diseases and other neurodegenerative disorders will likely benefit 
treatment development.  
Interestingly, the tumor suppressor gene p53 has been shown to mediate response of 
neurons to inflammation30 which brings into question the role of CLN proteins in this path-
way. Induction of p53 in response to IL-1β release causes induction of pro-apoptotic and 
cell cycle arrest signaling30. p53 induction occurs in response to inflammatory species like 
ROS and infections. Furthermore, p53 in cancer promotes inflammation, as well as de-
creases cell death and assists in maintaining cancer stem cells8. CLN3 upregulation has 
been demonstrated in hepatocellular carcinoma (HCC), and increased CLN3 expression in 
HCC tumors was correlated with more severe progression of HCC pathogenesis15. Consid-
ering the increased apoptosis as well as increased proliferation that are common to the CLN 
diseases, examination of the roles of CLN proteins in p53 signaling may prove useful. Fur-
thermore, Moumen et al. have examined a novel pathway involving mTOR-mediated 
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MDM2 activation, which causes inhibition of p53 to regulate cell survival35, which may 
show interaction with CLN proteins. Additional research should also be done to understand 
similarities and differences in cancer and CLN diseases, considering the apparently oppo-
site natures of tumor growth (decreased apoptosis and increased differentiation) and CLN 
deficiency (increased apoptosis, but decreased differentiation). 
As mTOR dysregulation is seen in many of the CLNs and some of these proteins 
function in breaking down intracellular material, the role of nutrient signaling should be 
considered in disease pathology. The mTOR pathway responds to many inputs, one of 
which is amino acids (Figure 8). Aggregation in response to nutrient deprivation as well 
as increased nutrient degradation has been seen in CLN2 Dictyostelium discodium, while 
increased protein turnover is seen in PGRN deficiency that may change the availability of 
cellular nutrients. Nutrient deprivation has been shown to increase perinuclear clustering 
of lysosomes and lead to inactivation of mTORC1. Nutrient replenishment increases wide-
spread distribution of lysosomes in the cell, and leads to mTORC1 reactivation37. Studies 
have indicated calorie intake and obesity may be linked to increased risk of neurodegener-
ative disorder such as Alzheimer’s disease, and antioxidants and vitamins have shown po-
tential benefits in protecting against harmful neurological effects of pro-inflammatory mol-
ecules16. Other studies have examined environmental factors in Alzheimer’s disease as 
well, indicating increased exposure to certain factors may increase the risk of disease with 
age47. Is there a role of nutrition in curbing symptoms associated with CLN diseases or 
disease progression, both in the affected patient as well as the mother during gestation? 
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Further examination of CLN involvement is mTOR regulation should also be considered, 
as this pathway has many potential implications in these diseases.  
 
Figure 8. The mTOR signaling pathway (Courtesy of Cusabio Technology). 
Lastly, comparison between phenotypes of allelic variation in CLN proteins can 
also provide insight into their functions. Heterozygous mutations in various CLN genes are 
known to produce alternate disease phenotypes, as seen in CLN2 (spinocerebellar ataxia, 
OMIM #609270), CLNs 4 and 6 (Kufs disease, OMIM #204300 and OMIM #60675), 
CLN7 (macular dystrophy, OMIM #61617), CLN8 (Northern epilepsy, OMIM #610003), 
and CLN11 (primary progressive aphasia and frontotemporal lobar dementia OMIM 
#607485). CLN genes have also been implicated in other neurodegenerative diseases14, 3. 
What happens to CLN expression in these CLN variants, and how do they contribute to 
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various neurodegenerative diseases? Answering these questions may give clues to the 
mechanisms involved in CLN pathogenesis. Understanding how modulations in autophagy 
caused by these proteins affects other diseases may help further research in this and other 
neurodegenerative disorders.  
Re-analysis of genomic data may also prove beneficial as more data accumulates 
regarding genetic variations in patients with NCLs. Whole exome sequencing is more often 
used as a diagnostic tool in the clinical setting. Al-Murshedi and coworkers recently high-
lighted the usefulness of whole exome reanalysis in resolving misdiagnosis of genetic dis-
eases1. Reanalysis of whole-exome data by Jedlickova et al., which identified a previously 
unknown mutation contributing to ANCL in one family, further exhibits the importance of 
data reanalysis64. 
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CONCLUDING REMARKS 
 NCLs and neurodegenerative disorders are incredibly devastating diseases, and the 
desire for answers comes with an increasingly large body of data to manage. While it is 
obviously important to observe any and all nuances associated with these diseases, I think 
it will become increasingly necessary to categorize data into subsets to obtain a better-
rounded image of how these diseases interact and progress. Meta-analyses are exception-
ally useful for this task. NCLs share many features with other neurodegenerative disorders, 
and comparative research will be useful in finding and understanding the connections be-
tween these types of diseases. Moreover, there may also be benefit in data comparisons 
between other non-CNS diseases, as has previously been done with Parkinson’s disease6, 
and Alzheimer’s disease2. As technology becomes smarter and the body of information 
expands, I am confident that finding the answers to treating and preventing neurodegener-
ative diseases is well within reach.  
 
  
   
 71
REFERENCES 
1.  Al-Murshedi F, Meftah D, Scott P. Underdiagnoses resulting from variant misinter-
pretation: Time for systematic reanalysis of whole exome data? European Journal of 
Medical Genetics. 2019;62(1):39-43. doi:10.1016/j.ejmg.2018.04.016 
2.  Carter CJ, France J, Crean S, Singhrao SK. The Porphyromonas gingivalis/Host In-
teractome Shows Enrichment in GWASdb Genes Related to Alzheimer’s Disease, 
Diabetes and Cardiovascular Diseases. Frontiers in Aging Neuroscience. 2017;9. 
doi:10.3389/fnagi.2017.00408 
3.  Marcos AL, Corradi GR, Mazzitelli LR, et al. The Parkinson-associated human P5B-
ATPase ATP13A2 modifies lipid homeostasis. Biochimica et Biophysica Acta (BBA) 
- Biomembranes. 2019;1861(10):182993. doi:10.1016/j.bbamem.2019.05.015 
4.  Connolly KJ, O’Hare MB, Mohammed A, et al. The neuronal ceroid lipofuscinosis 
protein Cln7 functions in the postsynaptic cell to regulate synapse development. Sci-
entific Reports. 2019;9(1):15592. doi:10.1038/s41598-019-51588-w 
5.  Sapir T, Segal M, Grigoryan G, et al. The Interactome of Palmitoyl-Protein Thioester-
ase 1 (PPT1) Affects Neuronal Morphology and Function. Frontiers in Aging Neuro-
science. 2019;13. doi:10.3389/fncel.2019.00092 
6.  Veeriah S, Taylor BS, Meng S, et al. Somatic mutations of the Parkinson’s disease-
associated gene PARK2 in glioblastoma and other human malignancies. Nature Ge-
netics. 2010;42(1):77-82. doi:10.1038/ng.491 
7.  Cárcel-Trullols J, Kovács AD, Pearce DA. Role of the Lysosomal Membrane Protein, 
CLN3, in the Regulation of Cathepsin D Activity. Journal of Cellular Biochemistry. 
2017;118(11):3883-3890. doi:10.1002/jcb.26039 
8.  Uehara I, Tanaka N. Role of p53 in the Regulation of the Inflammatory Tumor Mi-
croenvironment and Tumor Suppression. Cancers (Basel). 2018;10(7). 
doi:10.3390/cancers10070219 
9.  Tong CK, Vidyadaran S. Role of microglia in embryonic neurogenesis. Experimental 
Biology and Medicine (Maywood). 2016;241(15):1669-1675. 
doi:10.1177/1535370216664430 
10.  Takizawa P. Retina. Histology @ Yale. Accessed January 27, 2021. http://medcell. 
med.yale.edu/histology/sensory_systems_lab/retina.php 
11.  Purkinje cell | anatomy. Encyclopedia Britannica. Accessed March 11, 2021. 
https://www.britannica.com/science/Purkinje-cell 
   
 72
12.  Benedict JW, Getty AL, Wishart TM, Gillingwater TH, Pearce DA. Protein product 
of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscino-
sis interacts with CRMP-2. Journal of Neuroscience Research. 2009;87(9):2157-
2166. doi:https://doi.org/ 10.1002/jnr.22032 
13.  Ma Y, Matsuwaki T, Yamanouchi K, Nishihara M. Progranulin Protects Hippocam-
pal Neurogenesis via Suppression of Neuroinflammatory Responses Under Acute Im-
mune Stress. Molecular Neurobiology. 2017;54(5):3717-3728. doi:10.1007/s12035-
016-9939-6 
14.  Rayaprolu S, Seven YB, Howard J, et al. Partial loss of ATP13A2 causes selective 
gliosis independent of robust lipofuscinosis. Molecular and Cellular Neuroscience. 
2018;92:17-26. doi:10.1016/j.mcn.2018.05.009 
15.  Xu Y, Wang H, Zeng Y, et al. Overexpression of CLN3 contributes to tumour pro-
gression and predicts poor prognosis in hepatocellular carcinoma. Surgical Oncology. 
2019;28:180-189. doi:10.1016/j.suronc.2018.12.003 
16.  Gillette‐Guyonnet S, Secher M, Vellas B. Nutrition and neurodegeneration: epidemi-
ological evidence and challenges for future research. British Journal of Clinical Phar-
macology. 2013;75(3):738-755. doi:https://doi.org/10.1111/bcp.12058 
17.  Lyly A, von Schantz C, Heine C, et al. Novel interactions of CLN5 support molecular 
networking between Neuronal Ceroid Lipofuscinosis proteins. BMC Cell Biology. 
2009;10:83. doi:10.1186/1471-2121-10-83 
18.  Garcia-Manteiga JM, D’Alessandro R, Meldolesi J. News about the Role of the Tran-
scription Factor REST in Neurons: From Physiology to Pathology. International 
Journal of Molecular Sciences. 2020;21(1):235. doi:10.3390/ijms21010235 
19.  Ferguson SM. Neuronal Lysosomes. Neuroscience Letters. 2019;697:1-9. 
doi:10.1016/ j.neulet.2018.04.005 
20.  Persaud-Sawin D-A, Mousallem T, Wang C, Zucker A, Kominami E, Boustany R-
MN. Neuronal Ceroid Lipofuscinosis: A Common Pathway? Pediatric Research. 
2007;61(2):146-152. doi:10.1203/pdr.0b013e31802d8a4a 
21.  Henderson MX, Wirak GS, Zhang Y, et al. Neuronal ceroid lipofuscinosis with 
DNAJC5/CSPα mutation has PPT1 pathology and exhibit aberrant protein pal-
mitoylation. Acta Neuropathologica. 2016;131(4):621-637. doi:10.1007/s00401-
015-1512-2 
22.  Fabritius A-L, Vesa J, Minye HM, Nakano I, Kornblum H, Peltonen L. Neuronal ce-
roid lipofuscinosis genes, CLN2, CLN3 and CLN5 are spatially and temporally co-
expressed in a developing mouse brain. Experimental and Molecular Pathology. 
   
 73
2014;97(3):484-491. doi:10.1016/j.yexmp.2014.10.003 
23.  Vesa J, Chin MH, Oelgeschläger K, et al. Neuronal Ceroid Lipofuscinoses Are Con-
nected at Molecular Level: Interaction of CLN5 Protein with CLN2 and CLN3. Mo-
lecular Biology of the Cell. 2002;13(7):2410-2420. doi:10.1091/mbc.E02-01-0031 
24.  Ketscher A, Ketterer S, Dollwet-Mack S, Reif U, Reinheckel T. Neuroectoderm-spe-
cific deletion of cathepsin D in mice models human inherited neuronal ceroid 
lipofuscinosis type 10. Biochimie. 2016;122:219-226. doi:10.1016/j.bio-
chi.2015.07.020 
25.  Vesa J, Hellsten E, Verkruyse LA, et al. Mutations in the palmitoyl protein thioester-
ase gene causing infantile neuronal ceroid lipofuscinosis. Nature. 
1995;376(6541):584-587. doi:10.1038/376584a0 
26.  Reiner O. LIS1 and DCX: Implications for Brain Development and Human Disease 
in Relation to Microtubules. Scientifica. 2013;2013:393975. 
doi:10.1155/2013/393975 
27.  Laplante M, Sabatini DM. mTOR signaling at a glance. Journal of Cell Science. 
2009;122(20):3589-3594. doi:10.1242/jcs.051011 
28.  Smith PK, Sen MG, Fisher PR, Annesley SJ. Modelling of Neuronal Ceroid 
Lipofuscinosis Type 2 in Dictyostelium discoideum Suggests That Cytopathological 
Outcomes Result from Altered TOR Signalling. Cells. 2019;8(5). 
doi:10.3390/cells8050469 
29.  Dou Y, Wu H, Li H, et al. Microglial migration mediated by ATP-induced ATP re-
lease from lysosomes. Cell Research. 2012;22(6):1022-1033. doi:10.1038/cr.2012.10 
30.  Guadagno J, Swan P, Shaikh R, Cregan SP. Microglia-derived IL-1 β triggers p53-
mediated cell cycle arrest and apoptosis in neural precursor cells. Cell Death & Dis-
ease. 2015;6(6):e1779-e1779. doi:10.1038/cddis.2015.151 
31.  Sierra A, Encinas JM, Deudero JJP, et al. Microglia Shape Adult Hippocampal Neu-
rogenesis through Apoptosis-Coupled Phagocytosis. Cell Stem Cell. 2010;7(4):483-
495. doi:10.1016/ j.stem.2010.08.014 
32.  Xiong J, Kielian T. Microglia in juvenile neuronal ceroid lipofuscinosis are primed 
toward a pro-inflammatory phenotype. Journal of Neurochemistry. 2013;127(2):245-
258. doi:https:// doi.org/10.1111/jnc.12385 
33.  Soulet D, Rivest S. Microglia. Current Biology. 2008;18(12):R506-508. doi:10.1016/ 
j.cub.2008.04.047 
   
 74
34.  Huber RJ, Mathavarajah S, Yap SQ. Mfsd8 localizes to endocytic compartments and 
influences the secretion of Cln5 and cathepsin D in Dictyostelium. Cellular Signal-
ling. 2020;70:109572. doi:10.1016/j.cellsig.2020.109572 
35.  Moumen A, Patané S, Porras A, Dono R, Maina F. Met acts on Mdm2 via mTOR to 
signal cell survival during development. Development. 2007;134(7):1443-1451. 
doi:10.1242/ dev.02820 
36.  Leeman DS, Hebestreit K, Ruetz T, et al. Lysosome activation clears aggregates and 
enhances quiescent neural stem cell activation during aging. Science. 
2018;359(6381):1277-1283. doi:10.1126/science.aag3048 
37.  Korolchuk VI, Saiki S, Lichtenberg M, et al. Lysosomal positioning coordinates cel-
lular nutrient responses. Nature Cell Biology. 2011;13(4):453-460. 
doi:10.1038/ncb2204 
38.  Nieto-González JL, Gómez-Sánchez L, Mavillard F, et al. Loss of postnatal quies-
cence of neural stem cells through mTOR activation upon genetic removal of cysteine 
string protein-α. PNAS. 2019;116(16):8000-8009. doi:10.1073/pnas.1817183116 
39.  Singh Y, Leinonen H, Fazaludeen F, et al. Loss of Cln5 leads to altered Gad1 expres-
sion and deficits in interneuron development in mice. Human Molecular Genetics. 
2019;28(19):3309-3322. doi:10.1093/hmg/ddz165 
40.  Savchenko E, Singh Y, Konttinen H, et al. Loss of Cln5 causes altered neurogenesis 
in a mouse model of a childhood neurodegenerative disorder. Disease Models & 
Mechanisms. 2017;10(9):1089-1100. doi:10.1242/dmm.029165 
41.  Hester MS, Tulina N, Brown A, Barila G, Elovitz MA. Intrauterine inflammation re-
duces postnatal neurogenesis in the hippocampal subgranular zone and leads to accu-
mulation of hilar ectopic granule cells. Brain Research. 2018;1685:51-59. 
doi:10.1016/ j.brainres.2018.02.005 
42.  Goshen, I., Kreisel, T., Ben-Menachem-Zidon, O. et al. Brain interleukin-1 mediates 
chronic stress-induced depression in mice via adrenocortical activation and hippo-
campal neurogenesis suppression. Molecular Psychiatry 13, 717–728 (2008). 
https://doi.org/10.1038/ sj.mp.4002055 
43.  Radke J, Stenzel W, Goebel HH. Human NCL Neuropathology. Biochimica et Bio-
physica Acta (BBA) - Molecular Basis of Disease. 2015;1852(10, Part B):2262-2266. 
doi:10.1016/ j.bbadis.2015.05.007 
44.  Lyly A, von Schantz C, Salonen T, et al. Glycosylation, transport, and complex for-
mation of palmitoyl protein thioesterase 1 (PPT1) – distinct characteristics in neurons. 
BMC Cell Biology. 2007;8(1):22. doi:10.1186/1471-2121-8-22 
   
 75
45.  Mole SE, Cotman SL. Genetics of the Neuronal Ceroid Lipofuscinoses (Batten dis-
ease). Biochim Biophys Acta. 2015;1852(10 0 0):2237-2241. 
doi:10.1016/j.bbadis.2015.05.011 
46.  Yuan T-F. GABA Effects on Neurogenesis: An Arsenal of Regulation. Science Sig-
naling. 2008;1(15):jc1-jc1. doi:10.1126/stke.115jc1 
47.  Nicolia V, Lucarelli M, Fuso A. Environment, epigenetics and neurodegeneration: 
Focus on nutrition in Alzheimer’s disease. Experimental Gerontology. 2015;68:8-12. 
doi:10.1016/ j.exger.2014.10.006 
48.  Kobayashi T, Piao W, Takamura T, et al. Enhanced lysosomal degradation maintains 
the quiescent state of neural stem cells. Nature Communications. 2019;10(1):5446. 
doi:10.1038/s41467-019-13203-4 
49.  Götzl JK, Colombo A-V, Fellerer K, et al. Early lysosomal maturation deficits in mi-
croglia triggers enhanced lysosomal activity in other brain cells of progranulin knock-
out mice. Molecular Neurodegeneration. 2018;13. doi:10.1186/s13024-018-0281-5 
50.  Fan L-W, Pang Y. Dysregulation of neurogenesis by neuroinflammation: key differ-
ences in neurodevelopmental and neurological disorders. Neural Regeneration Re-
search. 2017;12(3):366-371. doi:10.4103/1673-5374.202926 
51.  Sjöqvist M, Andersson ER. Do as I say, Not(ch) as I do: Lateral control of cell fate. 
Developmental Biology. 2019;447(1):58-70. doi:10.1016/j.ydbio.2017.09.032 
52.  Burns JC, Cotleur B, Walther DM, et al. Differential accumulation of storage bodies 
with aging defines discrete subsets of microglia in the healthy brain. eLife. 9. 
doi:10.7554/eLife.57495 
53.  Galizzi G, Russo D, Deidda I, et al. Different early ER-stress responses in the 
CLN8mnd mouse model of neuronal ceroid lipofuscinosis. Neuroscience Letters. 
2011;488(3):258-262. doi:10.1016/j.neulet.2010.11.041 
54.  Kohlschütter A, Schulz A, Bartsch U, Storch S. Current and Emerging Treatment 
Strategies for Neuronal Ceroid Lipofuscinoses. CNS Drugs. 2019;33(4):315-325. 
doi:10.1007/s40263-019-00620-8 
55.  Wen Y, Bi P, Liu W, Asakura A, Keller C, Kuang S. Constitutive Notch Activation 
Upregulates Pax7 and Promotes the Self-Renewal of Skeletal Muscle Satellite Cells. 
Molecular and Cellular Biology. 2012;32(12):2300-2311. doi:10.1128/MCB.06753-
11 
56.  Lange J, Haslett LJ, Lloyd-Evans E, et al. Compromised astrocyte function and sur-
   
 76
vival negatively impact neurons in infantile neuronal ceroid lipofuscinosis. Acta Neu-
ropathologica Communications. 2018;6(1):74. doi:10.1186/s40478-018-0575-4 
57.  Chandra G, Bagh MB, Peng S, et al. Cln1 gene disruption in mice reveals a common 
pathogenic link between two of the most lethal childhood neurodegenerative lysoso-
mal storage disorders. Human Molecular Genetics. 2015;24(19):5416-5432. 
doi:10.1093/hmg/ddv266 
58.  Zhong NA, Moroziewicz DN, Ju W, Wisniewski KE, Jurkiewicz A, Brown WT. 
CLN -encoded proteins do not interact with each other. Neurogenetics. 2000;3(1):41-
44. doi:10.1007/PL00022978 
59.  Boustany R-M, Al-Shareef I, El-Haddad S. Chapter 104 - Sphingolipid Disorders and 
the Neuronal Ceroid Lipofuscinoses or Batten Disease (Wolman Disease, Cholesteryl 
Ester Storage Disease, and Cerebrotendinous Xanthomatosis). In: Rimoin D, Pyeritz 
R, Korf B, eds. Emery and Rimoin’s Principles and Practice of Medical Genetics. 
Academic Press; 2013:1-85. doi:10.1016/B978-0-12-383834-6.00109-9 
60.  McGuier NS, Uys JD, Mulholland PJ. Chapter 9 - Neural Morphology and Addiction. 
In: Torregrossa M, ed. Neural Mechanisms of Addiction. Academic Press; 2019:123-
135. doi:10.1016/B978-0-12-812202-0.00009-9 
61.  Markham A. Cerliponase Alfa: First Global Approval. Drugs. 2017;77(11):1247-
1249. doi:10.1007/s40265-017-0771-8 
62.  Kollmann K, Uusi-Rauva K, Scifo E, Tyynelä J, Jalanko A, Braulke T. Cell biology 
and function of neuronal ceroid lipofuscinosis-related proteins. Biochimica et Bio-
physica Acta (BBA) - Molecular Basis of Disease. 2013;1832(11):1866-1881. 
doi:10.1016/j.bbadis. 2013.01.019 
63.  Golabek AA, Kida E, Walus M, Wujek P, Mehta P, Wisniewski KE. Biosynthesis, 
Glycosylation, and Enzymatic Processingin Vivo of Human Tripeptidyl-peptidase I*. 
Journal of Biological Chemistry.2003;278(9):7135-7145. 
doi:10.1074/jbc.M211872200 
64.  Jedličková I, Cadieux-Dion M, Přistoupilová A, et al. Autosomal-dominant adult neu-
ronal ceroid lipofuscinosis caused by duplication in DNAJC5 initially missed by 
Sanger and whole-exome sequencing. European Journal of Human Genetics. 
2020;28(6):783-789. doi:10.1038/s41431-019-0567-2 
65.  Wu X, Fleming A, Ricketts T, et al. Autophagy regulates Notch degradation and mod-
ulates stem cell development and neurogenesis. Nature Communications. 
2016;7(1):10533. doi:10.1038/ncomms10533 
66.  Radke J, Koll R, Gill E, et al. Autophagic vacuolar myopathy is a common feature of 
   
 77
CLN3 disease. Annals of Clinical and Translational Neurology. 2018;5(11):1385-
1393. doi:https://doi.org/10.1002/acn3.662 
67.  Leung K-Y, Greene NDE, Munroe PB, Mole SE. Analysis of CLN3-protein interac-
tions using the yeasttwo-hybrid system. European Journal of Paediatric Neurology. 
2001;5:89-93. doi:10.1053/ejpn.2000.0441 
68.  Vidal-Donet JM, Cárcel-Trullols J, Casanova B, Aguado C, Knecht E. Alterations in 
ROS Activity and Lysosomal pH Account for Distinct Patterns of Macroautophagy 
in LINCL and JNCL Fibroblasts. PLOS ONE. 2013;8(2):e55526. doi:10.1371/jour-
nal.pone.0055526 
69.  Mahmood F, Fu S, Cooke J, Wilson SW, Cooper JD, Russell C. A zebrafish model 
of CLN2 disease is deficient in tripeptidyl peptidase 1 and displays progressive neu-
rodegeneration accompanied by a reduction in proliferation. Brain. 
2013;136(5):1488-1507. doi:10.1093/ brain/awt043 
70.  von Kleist L, Ariunbat K, Braren I, Stauber T, Storch S, Danyukova T. A newly gen-
erated neuronal cell model of CLN7 disease reveals aberrant lysosome motility and 
impaired cell survival. Molecular Genetics and Metabolism. 2019;126(2):196-205. 
doi:10.1016/ j.ymgme.2018.09.009 
71. Nishino I. Autophagic vacuolar myopathy. Seminars in Pediatric Neurology. 
2006;13(2):90-95. doi:10.1016/j.spen.2006.06.004 
72. Seehafer SS, Pearce DA. You say lipofuscin, we say ceroid: Defining autofluorescent 
storage material. Neurobiology of Aging. 2006;27(4):576-588. doi:10.1016/j.neurobi-
olaging. 2005.12.006 
73. Fey P, Kowal AS, Gaudet P, Pilcher KE, Chisholm RL. Protocols for growth and 
development of Dictyostelium discoideum. Nature Protocols. 2007;2(6):1307-1316. 
doi:10.1038/ nprot.2007.178 
74. Wu Y, Eghbali M, Ou J, Lu R, Toro L, Stefani E. Quantitative determination of spatial 
protein-protein correlations in fluorescence confocal microscopy. Biophysical Jour-
nal. 2010;98(3):493-504. doi:10.1016/j.bpj.2009.10.037 
75. Tuxworth RI, Vivancos V, O’Hare MB, Tear G. Interactions between the juvenile 
Batten disease gene, CLN3, and the Notch and JNK signalling pathways. Human Mo-
lecular Genetics. 2009;18(4):667-678. doi:10.1093/hmg/ddn396 
76. Xu H, Ren D. Lysosomal physiology. Annual Review of Physiology. 2015;77:57-80. 
doi:10.1146/annurev-physiol-021014-071649 
   
 78
77. Bagh MB, Peng S, Chandra G, et al. Misrouting of v-ATPase subunit V0a1 dysregu-
lates lysosomal acidification in a neurodegenerative lysosomal storage disease model. 
Nature Communications. 2017;8(1):14612. doi:10.1038/ncomms14612 
78. Berg DA, Bond AM, Ming GL, Song H. Radial glial cells in the adult dentate gyrus: 
what are they and where do they come from?. F1000Research. 2018;7:277. Published 
2018 Mar 5. doi:10.12688/f1000research.12684.1 
79. Ghosh H. Adult Neurogenesis and the Promise of Adult Neural Stem Cells. Journal 
of Experimental Neuroscience. 2019;13:117906951985687. 
doi:10.1177/1179069519856876 
  
   
 79
CURRICULM VITAE 
                                                      
   
 80
